CRISPR-mediated manipulation of APP expression as a therapeutic approach against amyloid pathology
CRISPR-mediated disruption of APP genomic sequences using Cas9 and sgRNAs addresses the ineffectiveness of current Alzheimer's treatments by reducing amyloid plaques and improving neural function, offering a promising therapeutic and preventive strategy.
Patent Information
- Application Number
- JP2024526778
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-04-25
- Filing Date
- 2022-10-28
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for neurodegenerative diseases such as Alzheimer's disease are ineffective and there is a high unmet need for better diagnostic and therapeutic methods due to limited understanding of the pathophysiology and increasing prevalence with the aging population.
Administering compositions that disrupt APP genomic sequences using CRISPR-mediated genome editing, including siRNAs, microRNAs, and antisense oligonucleotides, to target and modify specific regions within the APP gene, such as the Swedish mutation, using Cas9 nuclease and sgRNAs, delivered via AAV vectors for precise gene editing.
The method effectively reduces amyloid plaque burden, improves neural function, and ameliorates pathological lesions in animal models of Alzheimer's disease, providing a potential therapeutic and prophylactic approach.
Smart Images

Figure 2024542125000001_ABST
Abstract
Description
[Technical field]
[0001] Related Applications This application claims priority to U.S. Provisional Patent Application No. 63 / 272,689, filed October 28, 2021, and U.S. Provisional Patent Application No. 63 / 334,650, filed April 25, 2022, the contents of which are incorporated herein by reference in their entireties for all purposes. [Background technology]
[0002] Brain diseases, such as neurodegenerative and neuroinflammatory disorders, are devastating conditions that affect a large proportion of the population. Many of these diseases are incurable, highly debilitating, and often result in a progressive decline in brain structure and function over time. The growing aging population worldwide is also rapidly increasing disease prevalence, as older adults are at higher risk of developing these conditions. Currently, many neurodegenerative and neuroinflammatory diseases are difficult to diagnose due to a limited understanding of the pathophysiology of such diseases. Meanwhile, current treatments are ineffective and do not meet the market demand, a demand that is increasing significantly every year due to an ever-increasing aging population. For example, Alzheimer's disease (AD) is characterized by a slow but progressive decline in learning and memory and is the leading cause of death in the elderly. The increasing prevalence of AD is driving the need and demand for better and earlier diagnosis. According to the International Alzheimer's Society, the disease currently affects 46.8 million people worldwide, but the number of cases is expected to triple in the next 30 years. One of the fastest growing countries in the elderly population is China. Based on population projections, by 2030, one in four people will be over 60 years old, making a significant proportion of people at risk for developing AD. In fact, the number of AD cases in China doubled from 3.7 million to 9.2 million between 1990 and 2010, and the country is expected to have 22.5 million cases by 2050. Hong Kong's population is also rapidly aging. It is estimated that people aged 65 years and older will make up 24% of the population by 2025 and 39.3% of the population by 2050. The number of AD cases is expected to rise to 332,688 by 2039. Thus, there is an urgent need to develop new methods to effectively treat AD patients suffering from this devastating condition. The present invention fulfills this and other related needs by disclosing novel compositions and methods useful for the effective treatment of this disease, potentially providing a cure. Summary of the Invention [Means for solving the problem]
[0003] In a first aspect, the present invention provides a method for treating an amyloid pathology (such as Alzheimer's disease) in an individual, or reducing the risk of later development of the pathology in an individual, comprising administering to the individual an effective amount of a composition that disrupts a genomic sequence or transcript that includes the APP gene coding sequence.
[0004] In some embodiments, the method includes sequencing at least a portion of the individual's genome prior to the administering step. In some embodiments, the individual's APP genomic sequence includes at least one mutation, such as the Swedish mutation (K670N / M671L), the Florida mutation (I716V), the London mutation (V717I), or any combination thereof, as well as other genes with mutations or allelic variants associated with the formation of amyloid plaques. In some embodiments, the mutation includes the Swedish mutation (K670N / M671L). In some embodiments, the amyloid pathology is Alzheimer's disease (AD, including both familial AD and sporadic AD), cerebral amyloid angiopathy, or Down's syndrome. In some embodiments, the individual has been diagnosed with AD, while in other embodiments, the individual has not yet been diagnosed with AD but has known risk factors for AD, e.g., has certain genetic mutations known to increase the risk of AD, or has a family history of AD, particularly early-onset AD (e.g., before age 60 or 70). In some embodiments, the methods of the invention are carried out using a composition comprising an siRNA, microRNA, miniRNA, lncRNA, or antisense oligonucleotide targeted to an APP genomic sequence. In some embodiments, the methods utilize a CRISPR composition comprising: (1) an endonuclease guided by a small guide RNA (sgRNA) targeted to a location in the APP genomic sequence; and (2) one or more vectors encoding the sgRNA. In some embodiments, the sgRNA targets a region in the APP genomic sequence that contains a known mutation (e.g., Swedish mutation) or a region that contains a β-secretase cleavage site or a γ-secretase cleavage site, e.g., the targeted endonuclease cleavage site is within 2, 3, 5, 7, 8, 9, 10, 11, 12, or 15 nucleotides upstream or downstream of the mutation or secretase cleavage site.In some embodiments, the composition comprises a vector encoding a Cas9 nuclease (e.g., Streptococcus pyogenes Cas9 nuclease (SpCas9)) and an sgRNA. In some embodiments, the Cas9 and sgRNA are operably linked to and under the transcriptional control of a tissue-specific promoter, such as a neuronal cell-specific promoter known in the art or disclosed herein. In some embodiments, each of the one or more vectors is a viral vector, preferably an adeno-associated virus (AAV) vector. In some embodiments, the composition is administered by subcutaneous, intramuscular, intravenous, intraperitoneal, or intracranial injection, or by oral or nasal administration. In some embodiments, the composition is administered in the form of a solution, suspension, powder, paste, tablet, or capsule.
[0005] In a second aspect, the present invention provides compositions comprising an effective amount of one or more agents that disrupt APPP genomic sequences, and one or more physiologically acceptable non-medicinal excipients.
[0006] In some embodiments, the composition comprises an siRNA, microRNA, miniRNA, lncRNA, or antisense oligonucleotide targeted to an APP genomic sequence. In some embodiments, the method utilizes a CRISPR composition comprising: (1) an endonuclease guided by a small guide RNA (sgRNA) targeted to a location in the APP genomic sequence; and (2) one or more vectors encoding the sgRNA. In some embodiments, the sgRNA targets a region in the APP genomic sequence that contains a known mutation (e.g., the Swedish mutation) or a region that contains a β-secretase cleavage site or a γ-secretase cleavage site, e.g., the targeted endonuclease cleavage site is within 2, 3, 5, 7, 8, 9, 10, 11, 12, or 15 nucleotides upstream or downstream of the mutation or secretase cleavage site. In some embodiments, the composition comprises a vector encoding a Cas9 nuclease (e.g., Streptococcus pyogenes Cas9 nuclease (SpCas9)) and an sgRNA. In some embodiments, the Cas9 and sgRNA are operably linked to and under the transcriptional control of a tissue-specific promoter, such as a neuronal cell-specific promoter known in the art or disclosed herein. In some embodiments, each of the one or more vectors is a viral vector, preferably an adeno-associated virus (AAV) vector. In some embodiments, the composition is administered by subcutaneous, intramuscular, intravenous, intraperitoneal, or intracranial injection, or by oral or nasal administration. In some embodiments, the composition is administered in the form of a solution, suspension, powder, paste, tablet, or capsule.
[0007] In a third aspect, the invention provides a kit for treating an amyloid pathology (such as Alzheimer's disease) in an individual or reducing the risk of later development of said disease / condition in an individual, the kit comprising a first container housing a composition that disrupts an APP genomic sequence.
[0008] In some embodiments, the composition is formulated for subcutaneous, intramuscular, intravenous, intraperitoneal, or intracranial injection, or for oral or nasal administration. In some embodiments, the composition comprises an siRNA, microRNA, miniRNA, lncRNA, or antisense oligonucleotide that targets an APP genomic sequence. In some embodiments, the composition comprises (1) one or more vectors encoding an endonuclease guided by a small guide RNA (sgRNA), and (2) one sgRNA (or two sgRNAs) targeting one (or two) positions within the APP genomic sequence, e.g., one (or two) positions within a small region in close proximity to a preselected mutation (e.g., Swedish mutation) or a beta- or gamma-secretase cleavage site within the APP genomic sequence, such that the endonuclease cleavage site of interest is within 2, 3, 5, 7, 8, 9, 10, 11, 12, 15 nucleotides upstream or downstream of the mutation or secretase cleavage site. In some embodiments, the kit comprises a composition comprising a single vector encoding a Cas9 nuclease (e.g., Streptococcus pyogenes Cas9 nuclease (SpCas9)) and one or more sgRNAs. In some embodiments, the endonuclease and the sgRNA(s) may be encoded on two separate vectors. In some embodiments, the vector is a viral vector, such as one constructed based on adenovirus or adeno-associated virus (AAV). In some embodiments, the composition is administered by subcutaneous, intramuscular, intravenous, intraperitoneal, or intracranial injection, or by oral or nasal administration.In some embodiments, the kit further comprises a second container containing agents for sequencing at least a portion of an individual's genome (e.g., the APP gene and other genes that may have mutations or variants known to contribute to amyloid pathogenesis, such as presenilin 1 (PS1) and presenilin 2 (PS2), and APOE-ε4). Optionally, the kit also comprises instructions for administration of the composition.
[0009] With regard to this aspect of the invention, the disclosure herein further provides for the use of one or more agents that disrupt APP genomic sequences (1) for the manufacture of a medicament for treating amyloid pathologies (e.g., Alzheimer's disease); and / or (2) for the manufacture of a kit containing a medicament for treating amyloid pathologies (e.g., Alzheimer's disease). [Brief description of the drawings]
[0010] [Figure 1]Design and validation of CRISPR / Cas9-mediated genome editing to disrupt the mutant APPswe allele. a, The APP Swedish (APPswe) dinucleotide mutation (KM670 / 671NL) is located close to the β-secretase site. Two single guide RNAs (sgRNAs), SW1 and SW2, to target the APPswe mutation were designed using Staphylococcus aureus Cas9 (SaCas9). PAM, protospacer adjacent motif. Arrowheads indicate SaCas9 cleavage sites. b, Schematic of the EGxxFP system used to analyze the editing efficiency of the CRISPR / Cas9 system in vitro. The APPWT and APPswe sequences were separately inserted with overlapping arms between the EGFP fragment. SaCas9 (blue) editing led to homology-directed repair (HDR)-mediated DNA repair and reconstitution of the EGFP expression cassette, generating a GFP signal. c, In vitro validation of allele-specific editing using the EGxxFP system. Cas9-SW1 and Cas9-SW2 were co-transfected into HEK293T cells with EGxxFP reporter plasmids containing APPWT or APPswe, respectively (EGxxFP-APPWT or EGxxFP-APPswe). Scale bar: 100 μm. d, A single adeno-associated virus (AAV) vector EFS::Cas9-SW1 for intrahippocampal injection was constructed to express HA-tagged SaCas9 and sgRNA SW1. EFS, elongation factor 1-alpha short promoter; pA, poly(A) tail; U6, human U6 promoter; ITR, inverted terminal repeat. e, T7 endonuclease I assay of AAV-mediated Cas9-SW1 editing in the virally transduced hippocampus of 5XFAD mice. Arrowheads indicate CRISPR / Cas9-edited DNA fragments. Con, non-transduced hippocampal region of 5XFAD mice. f, Percentage of insertion / deletion (indel) mutations. CRISPR / Cas9 editing led to the formation of indel mutations. The percentage of indels indicates the editing efficiency. Values are means ± SEM (n = 3 mice / group; ***P < 0.001; unpaired two-tailed t-test).
[0011] [Diagram 2]Figure 1: Intrahippocampal AAV-mediated Cas9-SW1 editing reduces amyloid plaque burden in 5XFAD mice. AAV-mediated Cas9-SW1 intrahippocampal injection reduced amyloid beta (Aβ) levels and deposition in 3-month-old 5XFAD mice. a-c, Content of soluble and insoluble Aβ in dorsal hippocampal homogenates of 6-month-old 5XFAD mice after intrahippocampal injection of Cas9-SW1. a, Representative western blots of soluble and insoluble Aβ with GAPDH as a loading control (n=3 mice / group). b,c, Quantitative analysis of soluble and insoluble Aβx-40 and Aβx-42 by ELISA. Values are mean ± SEM (n=5 mice / group; *P<0.05, **P<0.01, ***P<0.001; unpaired two-tailed t-test). d-k, Amyloid plaque deposition was reduced in the hippocampal region of 5XFAD mice expressing AAV-mediated Cas9-SW1. Immunohistochemistry for Aβ (4G8; green), HA (red), and nuclei (blue). Representative images of distinct hippocampal regions (i.e., cornu ammonis and subiculum) from 6-month (d,e) and 9-month (h,i) 5XFAD mice. Expression of the HA tag indicates Cas9 expression. Scale bar: 50 μm. Quantification of Aβ-positive areas in cornu ammonis (f,j) and subiculum (g,k). Values are mean ± SEM (n = 4 mice / group; *P < 0.05, **P < 0.01; paired two-tailed t test).
[0012] [Diagram 3]Figure 1: Intrahippocampal AAV-mediated Cas9-SW1 editing reduces gliosis in 5XFAD mice. a,b,AAV-mediated Cas9-SW1 editing reduced microgliosis in the hippocampus of 5XFAD mice. Immunohistochemistry for Iba1 (red), amyloid beta (Aβ, 4G8; green), and nuclei (blue) in 6-month-old 5XFAD mice. a,Representative image of the subiculum. Scale bar: 50 μm (left), 10 μm (right). b,Quantification of Iba1 positive cells. Values are mean ± SEM (n = 3 mice / group; *P < 0.05; paired two-tailed t test). c-e,AAV-mediated Cas9-SW1 editing reduced astrocyte activation in the hippocampus of 5XFAD mice. Immunohistochemistry for GFAP (red), Aβ (4G8; green), and nuclei (blue) in 6-month-old 5XFAD mice. c, Representative images of the subiculum. Scale bars: 50 μm (left), 10 μm (right). d,e, AAV-mediated Cas9-SW1 editing in 5XFAD mice did not change astrocyte numbers but reduced astrocyte activation. d, Quantification of GFAP-positive cells. Values are means ± SEM (n = 4 mice / group; paired two-tailed t-test). e, Percentage of GFAP-positive area. Values are means ± SEM (n = 4 mice / group; *P < 0.05; paired two-tailed t-test).
[0013] [Figure 4]Figure 1: Intrahippocampal AAV-mediated Cas9-SW1 editing improves neuronal function in 5XFAD mice. a,b, AAV-mediated Cas9-SW1 editing reversed the reduction in long-term potentiation (LTP) in 6-month-old 5XFAD mice. LTP in the hippocampal CA1 region was induced by trains of four theta bursts. WT, wild type. a, Mean slope of field excitatory postsynaptic potentials (fEPSPs; mean ± SEM) normalized to baseline. (Inset) Examples of fEPSPs recorded 5 min before LTP induction (1, grey) and 55 min after LTP induction (2, black). b, Quantification of the mean slope of fEPSPs during the final 10 min of recording after LTP induction. Values are means ± SEM (WT Con n = 9 sections from 6 mice; 5XFAD Con n = 9 sections from 4 mice; 5XFAD SW1 n = 9 sections from 5 mice; **P < 0.01, ***P < 0.001; unpaired two-tailed t test). c-e, AAV-mediated Cas9-SW1 injection reduced the loss of excitatory synapses (PSD-95 [green] and synaptophysin [red] staining) in the subiculum of 9-month-old 5XFAD mice. c, Representative images. Scale bar: 5 μm. d,e, Quantification of PSD-95 puncta, synaptophysin puncta, and synaptophysin-PSD-95 colocalized puncta in the subiculum. Values are means ± SEM (n = 4 mice / group; *P < 0.05; paired two-tailed t test). f-i, AAV-mediated Cas9-SW1 editing reduced neurite degeneration and neuronal loss in the subiculum of 5XFAD mice. Co-staining for amyloid beta (Aβ, 4G8; green), nuclei (blue), and LAMP1 (a marker of neurite degeneration; red) in 6-month-old 5XFAD mice (f) or NeuN (red) in 9-month-old 5XFAD mice (g). Scale bars: 50 μm (f), 200 μm (g). h, Quantification of LAMP1-positive degenerated neurites. Values are means ± SEM (n = 3 mice / group; paired two-tailed t-test). i, Quantification of NeuN-positive cell density. Values are means ± SEM (n = 4 mice / group; *P < 0.05; paired two-tailed t-test).
[0014] [Diagram 5]Figure 1: Intrahippocampal AAV-mediated delivery of Cas9-SW1 reduces Alzheimer's disease-related pathology in APP / PS1 mice. AAV-mediated intrahippocampal injection of Cas9-SW1 reduced amyloid beta (Aβ) deposition and gliosis in 9-month-old APP / PS1 mice. a-d, Amyloid plaque deposition was reduced in the hippocampal region of APP / PS1 mice expressing AAV-mediated Cas9-SW1. a,b, Immunohistochemistry of Aβ (4G8; green), HA (red), and nuclei (blue) in 15-month-old APP / PS1 mice. Scale bar: 50 μm. Quantification of Aβ-positive plaque areas in the cornu ammonis (c) and subiculum (d). Values are mean ± SEM (n = 4 mice / group; *P < 0.05, **P < 0.01; paired two-tailed t-test). e-h, AAV-mediated Cas9-SW1 editing reduced gliosis in the subiculum of APP / PS1 mice. e, Immunohistochemistry for microglial markers Iba1 (red), Aβ (4G8; green), and nuclei (blue). Scale bars: 50 μm (left), 10 μm (right). f, Quantification of Iba1-positive cells. Values are mean ± SEM (n = 4 mice / group; *P < 0.05; paired two-tailed t test). g, Immunohistochemistry for astrocyte markers GFAP (red), Aβ (4G8; green), and nuclei (blue) in APP / PS1 mice. Scale bars: 50 μm (left), 10 μm (right). h, Quantification of GFAP-positive cells. Values are mean ± SEM (n = 4 mice / group; *P < 0.05; paired two-tailed t test). i, Percentage of GFAP-positive area. Values are means ± SEM (n = 4 mice / group; *P < 0.05; paired two-tailed t test).
[0015] [Figure 6]Figure 1: Systemic delivery of AAV-PHP.eB-mediated Cas9-SW1 globally reduces amyloid plaque burden in 5XFAD mice. a, Diagram of brain-wide APPswe editing. A single AAV vector for systemic administration, designated Cas9-mWPRE to express SW1-Syn::HA-tagged SaCas9 and sgRNA SW1, was designed with an AAV-PHP.eB capsid. ITR, inverted terminal repeat; U6, human U6 promoter; Syn, human synapsin 1 promoter; mWPRE, truncated woodchuck hepatitis virus (WHP) posttranscriptional regulatory element (WPRE); pA, poly(A) tail. b-d, Systemic injection of AAV-PHP.eB-mediated Cas9-SW1 in 3-month-old 5XFAD mice globally reduced amyloid beta (Aβ)-positive plaque area in the brain. b, Representative images of staining of amyloid plaques (i.e., 4G8) in 6-month-old 5XFAD mice after injection with AAV-PHP.eB:SW1-Syn::Cas9-mWPRE. Quantification of amyloid plaque area in the cortex (c) and hippocampus (d). Values are mean ± SEM (n = 4 mice / group; *P < 0.05, **P < 0.01; unpaired two-tailed t test). e-l, Reduction of X34-labeled amyloid plaque burden was associated with Cas9 expression in the brain. e,f,i,j, Immunohistochemistry of X34 (green), HA (red), and nuclei (blue) in the cornu ammonis (e), subiculum (f), cortex (i), and medulla oblongata (j) of 6-month-old 5XFAD mice. Expression of the HA tag indicates Cas9 expression. Scale bar: 50 μm. g,h,k,l, Quantification of X34-labeled plaque area. Values are means ± SEM (n = 4 mice / group; *P < 0.05, **P < 0.01; unpaired two-tailed t test).
[0016] [Figure 7]Figure 1: Systemic delivery of AAV-PHP.eB-mediated Cas9-SW1 reduces microgliosis and neurite degeneration and improves cognitive performance in 5XFAD mice. a,b, Systemic delivery of AAV-PHP.eB-mediated Cas9-SW1 reduced microgliosis in the subiculum in 3-month-old 5XFAD mice. a, Immunohistochemistry for Iba1 (red), amyloid beta (Aβ, 4G8; green), and nuclei (blue) in 6-month-old 5XFAD mice. Scale bars: 50 μm (left), 10 μm (right). b, Quantification of Iba1-positive microglia. Values are mean ± SEM (n = 4 mice / group; *P < 0.05; unpaired two-tailed t test). c,d, AAV-PHP.eB-mediated Cas9-SW1 editing reduced neurite degeneration in 5XFAD mice. c, Representative images showing staining for LAMP1 (a marker of neurite degeneration; red), Aβ (4G8; green), and nuclei (blue) in the subiculum of 6-month-old 5XFAD mice. Scale bar: 10 μm. d, Quantification of LAMP1-positive degenerated neurites. Values are mean ± SEM (n = 4 mice / group; **P < 0.01; unpaired two-tailed t test). e-g, Systemic delivery of AAV-PHP.eB-mediated Cas9-SW1 improved cognitive performance in 5XFAD mice. e, Systemic delivery of AAV-PHP.eB-mediated Cas9-SW1 improved habituation in the open field (OF) exploration test. Percentage change in distance traveled relative to the distance traveled on the first day of training. Values are mean ± SEM (n = 12 mice / group; *P < 0.05, **P < 0.01; two-way repeated measures ANOVA). f, Systemic delivery of AAV-PHP.eB-mediated Cas9-SW1 improved spatial working memory in the spontaneous alternation Y-maze test. Values are means ± SEM (n = 12 mice / group; *P < 0.05, **P < 0.01; unpaired two-tailed t test). g, Systemic delivery of AAV-PHP.eB-Cas9-SW1 led 5XFAD mice to spend significantly less time in the open arms. Values are means ± SEM (n = 12 mice / group; *P < 0.05; unpaired two-tailed t test).
[0017] [Figure 8]Validation of allele-specific editing in HEK293T cells and 5XFAD mice. a,b,Cas9-SW1 and Cas9-SW2 did not target APPWT. a,T7 endonuclease I mismatch assay of CRISPR / Cas9-mediated genome editing in HEK293T cells carrying APPWT alleles. WT1 and WT2 are single guide RNAs (sgRNAs) targeting APPWT alleles at the same locus as those of SW1 and SW2, respectively. b,Insertion / deletion (indel) rates were examined by targeted deep sequencing. Values are mean ± SEM (n = 5 replicates / group; ***P < 0.001; unpaired Student's t test). c,d,Off-target analysis of Cas9-SW1. c,Sequences of the top 5 predicted off-target sites in the human genome. d,T7EI assay of the top 5 predicted off-target sites in HEK293T cells. The absence of cleavage bands by T7EI indicates that the off-target activity of Cas9-SW1 was less than 1%. e-g, Validation of AAV-mediated Cas9-SW1 editing in vivo. e, The 10 most abundant APPswe sequences from Cas9-SW1-injected 5XFAD mouse brains measured by targeted deep sequencing. Mutation sites are indicated in blue text. Percentages are the frequencies of modified APPswe sequences. Editing events are indicated by "#". f, Number of somatic mutations detected by whole genome sequencing. Virus-transduced hippocampal regions (SW1) and non-transduced brain regions (Con) of the same mice were subjected to whole genome sequencing to detect somatic mutations. Values are mean ± SEM (n = 2 mice). g, Workflow for identification of potential off-target mutations.
[0018] [Figure 9]Figure 1 shows that intrahippocampal AAV-mediated Cas9-SW1 editing in 5XFAD transgenic mice reduces amyloid plaque deposition in Cas9-expressing brain regions. a,b, Immunohistochemistry of Aβ (4G8; green), HA (red), and nuclei (blue) in 6- or 9-month-old 5XFAD mice after intrahippocampal injection of AAV-mediated Cas9-SW1 (EFS::SaCas9-SW1) at 3 months of age. HA staining indicates Cas9 expression. a, Representative images of sagittal sections of control (Con) and virus-injected (SW1) 5XFAD mouse brains. Scale bar: 1 mm. b, Representative images of the hippocampus, cornu ammonis (CA), and subiculum of 6- and 9-month-old mice, respectively. Scale bar: 200 μm.
[0019] [Figure 10] Figure 1: Intrahippocampal AAV-mediated Cas9-SW1 editing reduces gliosis in the subiculum of 5XFAD mice. a,b Immunohistochemical analysis of amyloid plaque deposition in microglia (a) and astrocytes (b). Aβ (4G8; green) and nuclei (blue) were stained together with Iba1 (red; a) or GFAP (red; b), respectively, in 6-month-old mice (3 months after virus injection). Scale bar: 100 μm. WT, wild type.
[0020] [Figure 11] Figure 1: Intrahippocampal AAV-mediated Cas9-SW1 editing reduces neurite degeneration in 5XFAD mice. a,b Immunohistochemistry for LAMP1 (red), Aβ (4G8; green), and nuclei (blue) in the subiculum of 5XFAD mice at 6 months (a) and 9 months (b). Scale bar: 200 μm.
[0021] [Figure 12]Figure 1: Intrahippocampal AAV-mediated Cas9-SW1 editing reduces amyloid plaque deposition in Cas9-expressing brain regions of APP / PS1 transgenic mice. a, T7 endonuclease I assay of AAV-mediated Cas9-SW1 editing in virally transduced hippocampi of APP / PS1 mice. Arrowheads indicate CRISPR / Cas9-edited DNA fragments. Con, non-transduced hippocampal regions of APP / PS1 mice. b, Percentage of insertion / deletion (indel) mutations. Values are mean ± SEM (n = 4 mice / group; ***P < 0.001; unpaired two-tailed t test). c, d, Immunohistochemistry of Aβ (4G8; green), HA (red), and nuclei (blue) in 15-month-old APP / PS1 mice (6 months after virus injection). HA staining indicates Cas9 expression. c, Representative images of sagittal sections of APP / PS1 mouse brain. Scale bar: 1 mm. d, Representative images of the hippocampus, cornu ammonis (CA), and subiculum of the APP / PS1 mouse brain. Scale bar: 200 μm.
[0022] [Figure 13] Figure 1. Optimization of AAV constructs for improved gene transfer and robust expression in the central nervous system. a, Schematic comparison of two AAV vectors for systemic delivery (with or without insertion of mWPRE element). ITR, inverted terminal repeat; U6, human U6 promoter; Syn, human synapsin 1 promoter; mWPRE, truncated Woodchuck Hepatitis Virus (WHP) posttranscriptional regulatory element (WPRE); pA, poly(A) tail. b, Immunohistochemistry of HA (green) shows Cas9 expression in C57 mice injected with SW1-Syn::SaCas9 (-mWPRE) or SW1-Syn::SaCas9-mWPRE (+mWPRE) at a dose of 1x1012vg / mouse. Scale bar: 300 μm.
[0023] [Figure 14]Figure 1: Systemic delivery of AAV-PHP.eB-mediated Cas9-SW1 reduces amyloid plaque burden globally in 5XFAD mice. a, T7 endonuclease I assay of AAV-PHP.eB-mediated Cas9-SW1 editing in multiple brain regions of 5XFAD mice. Arrowheads indicate CRISPR / Cas9-edited DNA fragments. HP, hippocampus; Sub, subiculum; CA, cornu ammonis; DG, dentate gyrus; CX, cortex. b, Percentage of insertion / deletion (indel) mutations. CRISPR / Cas9 editing led to the formation of indel mutations. Percentage of indels indicates editing efficiency. Values are mean ± SEM (n = 3 mice / group). c, d, Immunohistochemistry of X34 (green), HA (red), and nuclei (blue) in 6-month-old 5XFAD mice after systemic administration of Cas9-SW1 (SW1-Syn::SaCas9-mWPRE). HA staining indicates Cas9 expression. c, Representative image of a sagittal section of a 5XFAD mouse brain 3 months after virus injection. Scale bar: 1 mm. d, Representative image of the hippocampus, cornu ammonis (CA), subiculum, and dentate gyrus (DG) of a 5XFAD mouse brain. Scale bar: 200 μm.
[0024] [Figure 15]Figure 1 shows that systemic delivery of AAV-PHP.eB-mediated Cas9-Con does not induce adverse effects in WT or 5XFAD mice. a-c, Systemic delivery of AAV-PHP.eB-mediated Cas9-Con did not induce adverse behavioral effects in wild-type (WT) mice. Uninject, uninjected. a, Systemic delivery of AAV-PHP.eB-mediated Cas9-Con did not change the locomotor activity of mice in the open field exploration test. Values are means ± SEM (n = 12 mice / group; unpaired two-tailed t-test). b, Systemic delivery of AAV-PHP.eB-mediated Cas9-Con did not change habituation in the open field (OF) exploration test. Percentage change in distance traveled compared to the distance traveled on the first day of training. Values are means ± SEM (n = 12 mice / group; unpaired two-tailed t-test). c, Systemic delivery of AAV-PHP.eB-mediated Cas9-Con did not affect spatial working memory in the spontaneous alternation Y-maze test. Values are means ± SEM (n = 12 mice / group; unpaired two-tailed t-test). d-f, Systemic delivery of AAV-PHP.eB-mediated Cas9-Con did not induce gliosis in WT mice. d, Immunohistochemistry of HA (red, left panel), Iba1 (red, center panel), GFAP (red, right panel), and nuclei (blue) in 6-month-old WT mice. Scale bar: 50 μm. e, Quantification of Iba1-positive cells. Values are means ± SEM (n = 4 mice / group; unpaired two-tailed t-test). f, Quantification of GFAP-positive cells. Values are means ± SEM (n = 4 mice / group). g,h, Immunohistochemistry of X34 (green), HA (red), and nuclei (blue) in 6-month-old 5XFAD mice after systemic administration of Cas9-Con (Con-Syn::SaCas9-mWPRE). Expression of the HA tag indicates Cas9 expression. Scale bars: 1 mm (g), 200 μm (h). i, Quantification of X34-labeled plaque area in the hippocampus of 6-month-old 5XFAD mice. Values are means ± SEM (n = 3 mice / group; unpaired two-tailed t-test).
[0025] [Figure 16]Figure 1. CRISPR targeting coverage of APP. Cas9-sgRNA complex specifically disrupts cleavage sites in exons 14-17 of APP. Figure adopted from Alzforum. 3'UTR, 3' untranslated region; AD, Alzheimer's disease; APP, amyloid precursor protein; Ex, exon.
[0026] [Figure 17] Figure 1 shows efficient deletion of APP in HEK293T cells. a, T7 endonuclease I mismatch assay of CRISPR / Cas9-mediated genome editing in HEK293T cells carrying the APPWT allele. WT1 and WT2 are single guide RNAs (sgRNAs) targeting the APPWT allele. SW1 and SW2 are sgRNAs targeting the APP Swedish mutation (serving as sgRNA controls; not relevant to the present invention). b, Insertion / deletion (indel) rates were examined by targeted deep sequencing. Values are mean ± SEM (n = 5 replicates / group; ***P < 0.001; unpaired Student's t test). APP, amyloid precursor protein; Con, control.
[0027] [Figure 18] CRISPR / Cas9-mediated deletion of the β-secretase site reduces APP expression and Aβ production in HEK293T cells. Representative western blot of APP with β-actin as a loading control. HEK293T cells were co-transfected with APP expression constructs and Cas9 / gRNA constructs. L, molecular size ladder; con, control; unt, untransfected. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0028] definition The term "APP" refers to the amyloid precursor protein or the gene encoding this protein. The human APP gene is located on human chromosome 21q11.2-q21 and encodes a protein having an exemplary amino acid sequence set forth herein as SEQ ID NO:2.
[0029] As used herein, the term "amyloid pathology" refers to a disease or condition caused or exacerbated by the accumulation of excessive amounts of amyloid plaques in relevant tissues and anatomical sites of an individual, such as the nervous system (such as the brain), blood vessel walls, and various organs. Examples of "amyloid pathology" include, but are not limited to, familial and sporadic Alzheimer's disease (AD), cerebral amyloid angiopathy, Down's syndrome, and various amyloidoses.
[0030] The term "nucleic acid" or "polynucleotide" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and polymers thereof in either single- or double-stranded form. Unless specifically limited, the term encompasses nucleic acids containing known analogs of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence implicitly encompasses not only the sequence explicitly stated, but also conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences. Specifically, degenerate codon substitutions can be obtained by creating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)). The term nucleic acid is used interchangeably with gene, cDNA, and gene-encoded mRNA.
[0031] The term "gene" refers to a DNA segment involved in producing a polypeptide chain, which may include regions preceding and following the coding region (leader and trailer), as well as intervening sequences (introns) between individual coding segments (exons).
[0032] The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that perform a similar function to naturally occurring amino acids. Naturally occurring amino acids are those encoded in the genetic code, as well as those that have been modified later, such as hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as naturally occurring amino acids, i.e., an α carbon bonded to a hydrogen, a carboxyl group, an amino group, and an R group, such as homoserine, norleucine, methionine sulfoxide, and methionine methylsulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as naturally occurring amino acids. "Amino acid mimetics" refer to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but perform a similar function to a naturally occurring amino acid.
[0033] A variety of methods are known in the art that allow for the site-specific incorporation of non-natural amino acid derivatives or analogues into a polypeptide chain, see, for example, WO02 / 086075.
[0034] Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides may likewise be referred to by their commonly accepted one-letter codes.
[0035] "Polypeptide," "peptide," and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. All three terms apply to amino acid polymers in which one or more amino acid residues are artificial chemical mimetics of the corresponding naturally occurring amino acids, as well as to naturally occurring and non-naturally occurring amino acid polymers. As used herein, these terms encompass amino acid chains of any length, including full-length proteins, in which the amino acid residues are linked by covalent peptide bonds.
[0036] As used herein, a "composition that disrupts an APP genomic sequence" refers to any composition comprising one or more agents capable of transcriptionally or translationally suppressing or eliminating the genomic sequence encoding the amyloid precursor protein (APP), which may be achieved by direct deletion or replacement of at least a portion of the APP genomic sequence (e.g., by genome editing techniques such as the clustered regularly interspaced short palindromic repeats (CRISPR) system), or by reduction or elimination of the mRNA transcribed from said genomic sequence through the action of small inhibitory DNA or RNA molecules or other enzymes (e.g., antisense oligonucleotides, small inhibitory RNAs such as siRNAs or shRNAs, and ribozymes, etc.), ultimately resulting in reduced expression of APP to the elimination of its protein expression.
[0037] The term "targeted," when used in the context of describing an inhibitory oligonucleotide (such as a small inhibitory RNA or antisense oligonucleotide) or sgRNA in the context of a genomic sequence that is to be negatively regulated using an inhibitory oligonucleotide or gene editing system, refers to the ability to allow specific hybridization between at least a portion of the oligonucleotide or sgRNA and the genomic sequence, between the sgRNA or oligonucleotide and the genomic sequence or its mRNA transcript, thereby subsequently targeting a predetermined location (e.g., a preselected mutation or a β-secretase cleavage site or an mRNA transcript thereof) in the APP genomic sequence. "canceled" indicates that there is sufficient sequence complementarity, e.g., 80% or more, 85% or more, 90% or more, 95% or more, based on Watson-Crick base pairing principles, to result in cleavage of the genomic sequence or destruction of its mRNA transcript (e.g., at a position near the mutation or the β-secretase cleavage site, e.g., within 3, 5, 7, 8, 10, 12, 15, or 20 nucleotides upstream or downstream of the β-secretase cleavage site or the γ-secretase cleavage site, or at a position near the mutation or the β-secretase cleavage site, e.g., within 3, 5, 7, 8, 10, 12, 15, or 20 nucleotides upstream or downstream of the γ-secretase cleavage site).
[0038] The term "recombinant," for example, when used with respect to a cell, or a nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein, or vector has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, for example, a recombinant cell expresses genes that are not found in the native (non-recombinant) form of the cell, or expresses genes that are naturally aberrantly expressed, under-expressed, or not expressed at all in the native state.
[0039] A "promoter" is defined as a set of nucleic acid control sequences that direct the transcription of a polynucleotide sequence. As used herein, a promoter includes necessary polynucleotide sequences near the transcription start site, such as a TATA element in the case of a polymerase II type promoter. A promoter also includes, optionally, distal enhancer or repressor elements, which may be located up to several thousand base pairs from the transcription start site. A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental control. The term "operably linked" refers to a functional linkage between a polynucleotide expression control sequence (such as a promoter or a set of transcription factor binding sites) and a second polynucleotide sequence, where the expression control sequence directs the transcription of the polynucleotide sequence corresponding to the second sequence.
[0040] An "expression cassette" is a nucleic acid construct, produced recombinantly or synthetically, with a specified series of polynucleotide elements that allow for the transcription of a particular polynucleotide sequence in a host cell. An expression cassette can be part of a plasmid, a viral genome, or a nucleic acid fragment. Typically, an expression cassette contains the polynucleotide to be transcribed operably linked to a promoter.
[0041] The term "heterologous", when used in the context of describing the corresponding positions of two elements, indicates that two elements, such as polynucleotide sequences (e.g., a promoter and an mRNA coding sequence or a protein / polypeptide coding sequence) or polypeptide sequences (e.g., two peptides as fusion partners in a fusion protein), are not found in the same corresponding positions in nature. Thus, a "heterologous promoter" of a coding sequence refers to a promoter that is not operably linked to the coding sequence in nature. Similarly, a "heterologous polypeptide" or "heterologous polynucleotide" of a particular protein or its coding sequence is one that originates from a different source than the particular protein, or one that originates from the same source but is not similarly linked to the particular protein or its coding sequence in nature. Fusion of a polypeptide (or its coding sequence) with a heterologous polypeptide (or polynucleotide sequence) does not result in a longer polypeptide or polynucleotide sequence that may be found in nature.
[0042] The phrase "specifically hybridizes to" refers to the binding, duplex formation, or hybridization of one polynucleotide sequence to another when present in a complex mixture (e.g., DNA or RNA in a whole cell or in a library) under stringent hybridization conditions based on Watson-Crick nucleotide base pairing. The phrase "stringent hybridization conditions" refers to conditions under which a nucleic acid (e.g., a polynucleotide probe) will hybridize to a target nucleotide sequence but not to other sequences, usually in a complex mixture of nucleic acids. Stringent conditions are sequence-dependent and will be different in different environments. Longer sequences hybridize specifically at higher temperatures. For an extensive introduction to nucleic acid hybridization, see Tijssen, Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Generally, stringent conditions are defined by the thermal melting point (T m ) is selected to be about 5 to 10°C lower than T m is the temperature (under defined ionic strength, pH, and nucleic acid concentration) at which 50% of the probes complementary to the target hybridize to the target sequence and are in equilibrium (because the target sequences are present in excess, T m(At pH 7.0-8.3, 50% of the probes are occupied and in equilibrium). Stringent conditions are those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01-1.0 M sodium ion concentration (or other salts) at pH 7.0-8.3, and the temperature is at least about 30° C. for short probes (e.g., 10-50 nucleotides) and at least about 60° C. for long probes (e.g., more than 50 nucleotides). Stringent conditions can also be obtained by the addition of destabilizing agents such as formamide. For high stringency hybridization, a positive signal is at least two times background, preferably 10 times background hybridization. Exemplary high stringency hybridization conditions include: 50% formamide, 5xSSC and 1% SDS with incubation at 42°C or 5xSSC and 1% SDS with incubation at 65°C with a wash in 0.2xSSC and 0.1% SDS at 65°C.
[0043] By "host cell" is intended a cell that harbors an expression vector and supports the replication or expression of said expression vector. Host cells can be prokaryotic cells such as E. coli, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells such as CHO and HeLa, including cultured cells, explants, and cells in vivo.
[0044] The term "inhibit" or "inhibition", as used herein, refers to any detectable negative effect that an inhibitor has on a biological process of interest, such as expression of APP protein, formation of amyloid beta (Aβ) plaques in the brains of AD patients, cognitive decline in AD patients, protein phosphorylation, cell signaling, protein synthesis, cell proliferation, tumorigenicity, and metastatic potential. Typically, inhibition is reflected in a 10% or more, 20% or more, 30% or more, 40% or more, or 50% or more decrease in the process of interest (e.g., expression of APP protein or accumulation of Aβ plaques), or any one of the above downstream parameters, when compared to a control not exposed to the inhibitor. Similarly, the terms "enhance" or "enhancement" are used to indicate any detectable positive effect, such as a positive change of 25% or more, 50% or more, 75% or more, 100% or more, or 2-fold higher, 3-fold higher, 4-fold higher, 5-fold higher, or up to 10-fold higher or up to 20-fold higher, that an enhancer has on a biological process of interest when compared to a control without said enhancer. Conversely, the term "substantially unchanged" refers to a positive or negative change of less than 10%, less than 5%, less than 2%, less than 1%, or less.
[0045] The term "effective amount" as used herein refers to an amount sufficient to produce the intended effect of administering a substance. The effect may include desirable changes in biological processes (e.g., detectable reduction in APP expression, reduction in the formation of Aβ plaques, or slowing down cognitive decline in AD patients), as well as prevention, amelioration, or arrest of the progression of symptoms of disease / pathology and associated complications to any detectable extent. The exact amount that is "effective" to produce the desired effect depends on the nature of the therapeutic agent, the mode of administration, and the purpose of treatment, and can be ascertained by those skilled in the art using known techniques (see, for example, Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); and Pickar, Dosage Calculations (1999)).
[0046] As used herein, the term "treatment" or "treating" includes both therapeutic and preventive measures taken to address the presence of a disease or condition or the risk of developing such a disease or condition at a later time. The term encompasses therapeutic or preventive measures to alleviate currently occurring symptoms, inhibiting or slowing disease progression, delaying the onset of symptoms, or eliminating or reducing side effects caused by such a disease or condition. Preventive measures and variations thereof in this context do not require 100% elimination of the occurrence of an event, rather, it refers to inhibiting or reducing the likelihood or severity of such occurrence or delaying such occurrence.
[0047] A "pharmacologically acceptable" or "pharmacologically acceptable" non-excipient is a substance that is not biologically harmful or undesirable, i.e., the non-excipient may be administered to an individual along with a bioactive agent without causing undesirable biological effects. Any non-excipient is not expected to adversely interact with any of the components of the composition in which it is included.
[0048] The term "non-medicinal ingredients" refers to any substances that are accessory in nature that may be present in the final dosage form of the composition of the present invention. For example, the term "non-medicinal ingredients" includes vehicles, binders, disintegrants, fillers (diluents), lubricants, glidants (flow improvers), compression aids, colorants, sweeteners, preservatives, suspending / dispersing agents, film formers / coatings, flavorings, and printing inks.
[0049] The term "consisting essentially of," when used in the context of describing a composition comprising an active ingredient or active ingredients, refers to the fact that the composition does not contain any other ingredients that have any biological activity similar to or related to the biological activity of the active ingredient(s) or that can enhance or inhibit said activity, while one or more inactive ingredients, such as physiologically acceptable non-medicinal ingredients or pharma- ceutically acceptable non-medicinal ingredients, may be present in the composition. For example, a composition consisting essentially of active agent(s) effective to disrupt an APP genomic sequence or to inhibit mRNA transcribed from a genomic sequence of a subject is a composition that does not contain any other agents that may have any detectable positive or negative effect on the same target process or that may increase or decrease to any measurable extent the occurrence or symptoms of a disease in a subject to which the composition is administered.
[0050] The term "about" refers to a range of + / - 10% of a given value. For example, "about 10" is defined as a range of 90% to 110% of 10, i.e., 9 to 11.
[0051] Detailed Description of the Invention I. Introduction The correlation between abnormal amyloid plaque accumulation and various pathologies such as Alzheimer's disease (AD) has been observed and understood for a long time. The present inventors have used CRISPR-based genome editing to target one or more specific subregions (e.g., within close proximity to preselected mutation sites or β-secretase or γ-secretase cleavage sites) in the genomic sequence of amyloid precursor protein (APP), and have succeeded in achieving inhibition of amyloid plaque accumulation for the first time ever, with little off-target editing detected. Thus, it has been demonstrated that such disruption of the APP genomic sequence provides therapeutic benefits in the treatment of patients suffering from excessive accumulation of amyloid plaques in the brain and other organs in various pathologies (such as AD) in which amyloid plaques play a key role in the development and progression of the disease, as well as prophylactic benefits in preventing or reducing the risk of this disease in individuals who have not yet been diagnosed with such a disease but may have a known risk, such as a family history of AD.
[0052] II. General Recombinant Technology Basic texts disclosing general methods and techniques in the field of recombinant genetics include Sambrook and Russell, Molecular Cloning, A Laboratory Manual (3rd ed. 2001); Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); and Ausubel et al., eds., Current Protocols in Molecular Biology (1994).
[0053] For nucleic acids, sizes are given in either kilobases (kb) or base pairs (bp). These are estimates calculated from agarose or acrylamide gel electrophoresis, from sequenced nucleic acids, or from published DNA sequences. For proteins, sizes are given in kilodaltons (kDa) or amino acid residue numbers. Protein sizes are estimated from gel electrophoresis, from sequenced proteins, from derived amino acid sequences, or from published protein sequences.
[0054] Oligonucleotides that are not commercially available can be chemically synthesized, for example, by the solid-phase phosphoramidite triester method first reported in Beaucage & Caruthers, Tetrahedron Lett. 22:1859-1862 (1981), using an automated synthesizer such as that described in Van Devanter et. al., Nucleic Acids Res. 12:6159-6168 (1984). Purification of oligonucleotides can be performed by any means commonly accepted in the art, such as native acrylamide gel electrophoresis, or anion-exchange HPLC as described in Pearson & Reanier, J. Chrom. 255:137-149 (1983).
[0055] The sequence of the gene of interest, the sequence of the polynucleotide encoding the polypeptide of interest, and the sequence of the synthetic oligonucleotides can be verified after cloning or subcloning, for example, using the chain termination method of Wallace et al., Gene 16:21-26 (1981) for sequencing of double-stranded templates.
[0056] II. Compositions that disrupt genomic sequences Previous studies by the present inventors and others have explained the involvement of APP and its mutations in the development of Alzheimer's disease. Recent discoveries have revealed that, in particular, preselected mutations (e.g., Swedish mutation) or disruption of APP genomic sequences adjacent to the β-secretase or γ-secretase cleavage sites can effectively and significantly reduce APP expression and Aβ plaque accumulation in the brain. This finding leads to therapeutic and prophylactic use of compositions that disrupt this genomic sequence to treat Alzheimer's disease in patients already diagnosed with the disease, as well as to prevent / reduce the risk of later onset of the disease in individuals who have not yet been diagnosed but are at high risk for Alzheimer's disease due to, for example, family history or known genetic background (e.g., carriers of one or two APOE ε4 alleles, a point mutation in the genomic sequence encoding the amyloid precursor protein (APP) on chromosome 21, a point mutation in the genomic sequence encoding presenilin 1 (PSEN1) on chromosome 14, and a point mutation in the genomic sequence encoding presenilin 2 (PSEN2) on chromosome 1), either at the level of the complete genomic sequence at or immediately surrounding a specific mutation or a preselected genomic locus of a β-secretase or γ-secretase cleavage site, or either at the level of the mRNA transcribed from the genomic sequence. Various categories of potential agents that act by different mechanisms (eg, by genome editing or mRNA suppression) are useful in formulating such compositions for disruption of APP genomic sequences and are discussed below.
[0057] A. Antisense Oligonucleotides In some embodiments, the agent useful for disrupting APP genomic sequence is an antisense oligonucleotide.Antisense oligonucleotides are relatively short nucleic acids that are complementary (or antisense) to the coding strand (sense strand) of the RNA transcribed from the genomic sequence that contains the APP gene.Antisense oligonucleotides are usually RNA-based, but can also be DNA-based.Antisense oligonucleotides are often modified to increase their stability.
[0058] Without being bound by theory, it is believed that when these relatively short oligonucleotides bind to mRNA, they induce double-stranded RNA strands that induce the degradation of this messenger by endogenous RNA degradation enzymes.Furthermore, in some cases, these oligonucleotides are specifically designed to bind near the promoter of coding sequence, and under such circumstances, antisense oligonucleotides can also interfere with the translation of mRNA.Regardless of the specific mechanism by which antisense oligonucleotides function, their administration to cells or tissues allows the degradation of RNA transcribed from genomic sequences, including APP gene.Therefore, antisense oligonucleotides reduce the expression and / or activity of the product coded from genomic sequence.
[0059] The oligonucleotides can be single- or double-stranded, DNA or RNA, or chimeric mixtures, derivatives, or modified versions thereof. The oligonucleotides may be modified at the base moiety, sugar moiety, or phosphate backbone to improve, for example, the stability, hybridization, etc. of the molecule. The oligonucleotide may contain other appending groups such as peptides (e.g., for targeting a host cell receptor) or agents that facilitate transport across a cell membrane (see, e.g., Letsinger et al., 1989, Proc. Natl. Acad. Sci. USA 86:6553-6556; Lemaitre et al., 1987, Proc. Natl. Acad. Sci. 84:648-652; WO88 / 09810) or agents that facilitate transport across the blood-brain barrier (see, e.g., WO89 / 10134), hybridization-triggered cleavage agents (see, e.g., Krol et al., 1988, BioTechniques 6:958-976), or intercalating agents (see, e.g., Zon, 1988, Pharm. Res. 5:539-549). For this purpose, the oligonucleotide may be conjugated to another molecule.
[0060] The oligonucleotide of the present invention can be synthesized by standard methods known in the art, for example, by using an automatic DNA synthesizer (such as those commercially available from Biosearch, Applied Biosystems, etc.).As an example, phosphorothioate oligonucleotide can be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 16:3209), and methylphosphonate oligonucleotide can be prepared by using controlled pore glass polymer support (Sarin et al., 1988, Proc. Natl. Acad. Sci. USA 85:7448-7451).
[0061] Several methods have been developed for delivering antisense DNA or antisense RNA to cells; for example, antisense molecules can be directly injected into the target anatomical site, or modified antisense molecules designed to target desired cells (e.g., antisense linked to a peptide or antibody that specifically binds to a receptor or antigen expressed on the surface of a target cell) can be administered systemically.
[0062] Achieving sufficient intracellular antisense concentrations to suppress translation of endogenous mRNAs can be difficult in some cases. Therefore, another approach utilizes recombinant DNA constructs in which antisense oligonucleotides are placed under the control of a strong pol III or pol II promoter. For example, a vector can be introduced in vivo to be taken up by cells and direct the transcription of antisense RNA. Such vectors can remain episomal or chromosomally integrated as long as they can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. The vectors can be plasmid, viral, or other known in the art, used for replication and expression in mammalian cells. Expression of the sequence encoding the antisense RNA can be by any promoter known in the art that acts in mammalian cells, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to: the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained within the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., 1980, Cell 22:787-797), herpes virus thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. USA 78:1441-1445), the regulatory sequence of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42), etc. Any type of plasmid, cosmid, YAC, or viral vector can be used to prepare recombinant DNA constructs that can be directly introduced into the target tissue site. Alternatively, viral vectors can be used which selectively infect the desired tissue, in which case administration can be by another route (eg, systemically).
[0063] B. Small interfering RNA In some embodiments, the agent is a small interfering RNA (siRNA or RNAi) molecule. The RNAi construct comprises a double-stranded RNA that can specifically block the expression of a target gene. "RNA interference" or "RNAi" is a term originally applied to the phenomenon that double-stranded RNA (dsRNA) specifically and post-transcriptionally blocks gene expression. RNAi provides a useful method of inhibiting gene expression in vitro or in vivo. RNAi constructs can include small interfering RNA (siRNA), small hairpin RNA (shRNA), and other RNA species that can be cleaved in vivo to form siRNA. The RNAi construct herein also includes an expression vector ("RNAi expression vector") that can provide a transcript that forms dsRNA or hairpin RNA in a cell, and / or a transcript that can generate siRNA in vivo.
[0064] The RNAi expression vector expresses (transcribes) an RNA that produces an siRNA portion in the cell in which the construct is expressed. Such a vector includes a transcription unit that includes (1) a genetic element(s) that plays a regulatory role in gene expression (e.g., promoter, operator, or enhancer), (2) a "coding" sequence that is operably linked to (1) and that is transcribed to produce a double-stranded RNA (two RNA portions that anneal to form siRNA in the cell, or a single hairpin RNA that can be processed into siRNA), and (3) an assembly with appropriate transcription start and termination sequences. The choice of promoter and other regulatory elements generally depends on the host cell of interest.
[0065] The RNAi construct comprises a nucleotide sequence that hybridizes to at least a portion of the nucleotide sequence of the mRNA transcript (i.e., the RNA transcribed from the genomic sequence including the APP gene) of the gene to be inhibited under physiological conditions of the cell. All that is required of the double-stranded RNA is that it is sufficiently similar to natural RNA that it has the ability to mediate RNAi. Thus, the present invention has the advantage of being able to tolerate sequence diversity that may be expected due to genetic mutation, lineage polymorphism, or evolutionary divergence. The number of nucleotide mismatches tolerated between the target sequence and the sequence of the RNAi construct is no more than 1 in 5 base pairs, no more than 1 in 10 base pairs, no more than 1 in 20 base pairs, or no more than 1 in 50 base pairs. Mismatches in the center of the siRNA duplex are most critical, and may essentially disable cleavage of the target RNA. In contrast, the nucleotides at the 3' end of the siRNA strand that is complementary to the target RNA do not significantly contribute to the specificity of target recognition.
[0066] The RNAi constructs may be produced by chemical synthesis methods or by recombinant nucleic acid techniques. Endogenous RNA polymerases of treated cells may mediate transcription in vivo, or cloned RNA polymerases may be used for transcription in vitro. The RNAi constructs may contain modifications to either the phosphate-sugar backbone or the nucleosides, for example, to reduce susceptibility to intracellular nucleases, improve bioavailability, improve formulation properties, and / or alter other pharmacokinetic properties. For example, the phosphodiester bonds of natural RNA may be modified to include at least one of a nitrogen or sulfur heteroatom. Modifications of the RNA structure may be tailored to avoid a general response to dsRNA but allow specific gene inhibition. Similarly, bases may be modified to inhibit the activity of adenosine deaminase. The RNAi constructs may be produced enzymatically or partially / fully by organic synthesis, and any modified ribonucleotides may be introduced by enzymatic or organic synthesis in vitro.
[0067] In certain embodiments, the subject RNAi constructs are "small interfering RNAs" or "siRNAs." Such nucleic acids are on the order of 19-30 nucleotides in length, and even more preferably 21-23 nucleotides in length, e.g., lengths corresponding to fragments generated by nuclease "dicing" of long double-stranded RNA. siRNAs are understood to recruit and guide nuclease complexes to target mRNAs by pairing with specific sequences. As a result, the target mRNA is degraded by nucleases within the protein complex. In certain embodiments, the 21-23 nucleotide siRNA molecules contain a 3' hydroxyl group.
[0068] In certain embodiments, the RNAi construct is in the form of a short hairpin structure (referred to as shRNA). shRNA may be exogenously synthesized or formed by transcription in vivo with an RNA polymerase III promoter. Examples of the creation and use of such hairpin RNA for gene silencing in mammalian cells are described, for example, in Paddison et al., Genes Dev, 2002, 16:948-58; McCaffrey et al., Nature, 2002, 418:38-9; Yu et al., Proc Natl Acad Sci USA, 2002, 99:6047-52). In many cases, such shRNA is designed to ensure continuous and stable suppression of the desired gene in cells or animals. It is known in the art that siRNA can be produced by processing hairpin RNA in cells.
[0069] Plasmids can be used to deliver double-stranded RNA, for example as a transcription product. In such an embodiment, the plasmid is designed to contain the "coding sequence" of each of the sense and antisense strands of the RNAi construct. The coding sequence can be the same sequence, for example, flanked by inverted promoters, or it can be two separate sequences, each under the transcriptional control of a separate promoter. After the coding sequence is transcribed, the complementary RNA transcripts base pair to form double-stranded RNA.
[0070] C. Ribozyme In some embodiments, the agent is a ribozyme. Ribozyme molecules designed to catalytically cleave mRNA transcripts are also used to destroy mRNA and suppress its downstream effects (see, for example, WO90 / 11364; Sarver et al., 1990, Science 247:1222-1225 and U.S. Patent No. 5,093,246). Ribozymes that cleave mRNA at site-specific recognition sequences can be used to destroy specific mRNAs, but the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at positions dictated by adjacent regions that form complementary base pairs with the target mRNA. The only requirement is that the target mRNA has the dinucleotide sequence 5'-UG-3'. The construction and production of hammerhead ribozymes are well known in the art and are described more fully in Haseloff and Gerlach, 1988, Nature, 334:585-591.
[0071] Ribozymes for use in the present invention may also include RNA endoribonucleases such as those naturally occurring in the ciliate Tetrahymena (known as IVS, or L-19 IVS RNA) (hereinafter "Cech-type ribozymes") and have been extensively described by Thomas Cech and coworkers (Zaug, et al., 1984, Science, 224:574-578; Zaug and Cech, 1986, Science, 231:470-475; Zaug, et al., 1986, Nature, 324:429-433; WO88 / 04300; Been and Cech, 1986, Cell, 47:207-216). Cech-type ribozymes have an eight base pair active site that hybridizes to a target RNA sequence after which cleavage of the target RNA occurs. The present invention encompasses Cech-type ribozymes that target eight base pair active site sequences.
[0072] As in the case of antisense approaches, ribozymes may be composed of modified oligonucleotides (e.g., for improved stability, targeting, etc.) and may be delivered to cells in vitro or in vivo. One preferred delivery method involves the use of a DNA construct "encoding" a ribozyme under the control of a strong constitutive pol III or pol II promoter, such that the transfected cell produces sufficient amounts of ribozyme to destroy the targeted mRNA and inhibit its effect. Ribozymes, unlike antisense molecules, are catalytic and therefore require lower intracellular concentrations for efficiency.
[0073] Currently, there are two basic types of DNA enzymes, both of which were identified by Santoro and Joyce (see, e.g., U.S. Pat. No. 6,110,462).10-23 DNA enzymes contain a loop structure connecting two arms that provide specificity by recognizing a particular target nucleic acid sequence, while the loop structure provides catalytic function under physiological conditions.
[0074] Briefly, to design an ideal DNA enzyme that specifically recognizes and cleaves a target nucleic acid, one skilled in the art must first identify the target unique sequence. This can be done using the same approach outlined for antisense oligonucleotides. Preferably, this unique or substantial sequence is G / C rich, approximately 18-22 nucleotides. High G / C content helps ensure a stronger interaction between the DNA enzyme and the target sequence.
[0075] When synthesizing a DNA enzyme, a specific antisense recognition sequence capable of targeting the enzyme to a messenger is split to comprise the two arms of the DNA enzyme, with the DNA enzyme loop positioned between the two specific arms.
[0076] For methods of making and administering DNA enzymes, see, for example, U.S. Patent No. 6,110,462. Similarly, methods of delivering DNA ribozymes in vitro or in vivo include methods of delivering RNA ribozymes as outlined in detail above. Furthermore, those skilled in the art will recognize that, like antisense oligonucleotides, DNA enzymes can be modified, if desired, to improve stability and resistance to degradation.
[0077] D. Genome Editing Inhibition of APP expression can be achieved by disrupting the gene sequence that contains the coding sequence of this protein. One effective means of targeted gene cleavage is the CRISPR system.
[0078] The term CRISPR is an abbreviation for Clustered Regularly Interspaced Short Palindromic Repeats, a term originally coined for prokaryotic DNA segments containing short repeated base sequences first found in bacteria and archaea. In palindromic repeats, the sequence of nucleotides is the same in both directions. Each repeat is followed by a short segment of spacer DNA derived from previous exposure to foreign DNA (e.g., viral DNA). Small clusters of Cas (CRISPR-associated) genes are present next to the CRISPR sequences. The CRISPR / Cas system was later recognized as a prokaryotic immune system that confers resistance to foreign genetic elements, especially those of viral origin, thereby providing acquired immunity. RNA with spacer sequences helps Cas (CRISPR-associated) proteins to recognize and cleave foreign DNA. Other RNA-guided Cas proteins cleave foreign RNA. CRISPR is found in approximately 50% of sequenced bacterial genomes and nearly 90% of sequenced archaeal genomes, and recently the CRISPR / Cas system has been adapted for use in targeted gene editing in eukaryotic cells. See, e.g., Ledford (2016), Nature 531 (7593):156-9.
[0079] A simple version of the CRISPR / Cas system, CRISPR / Cas9, has been engineered for genome editing. Cas9 nuclease complexed with one or more synthetic guide RNAs (gRNAs) can be delivered into a cell, usually by transfecting the cell with one or more expression vectors encoding the Cas9 nuclease and gRNA(s), to cut the cell's genome at one or more preselected locations, allowing the target gene (e.g., the genomic sequence carrying rs1921622) to be removed and / or replaced with a new sequence.
[0080] In this case, an expression vector (e.g., a viral vector such as an adeno-associated virus or an AAV vector) carrying the coding sequence of one or more gRNAs specific to the targeted subregion of the APP genomic sequence can be introduced into the cell (e.g., a neuronal cell) in which the endogenous APP genomic sequence is to be knocked out. The same expression vector can optionally also carry the coding sequence of a CRISPR / Cas9 nuclease or equivalent. In other cases, a separate expression vector can be used to introduce the CRISPR / Cas9 nuclease coding sequence for expression in the target cell. In some cases, more than one (e.g., two) different gRNAs are used to ensure the removal and / or replacement of the targeted genomic sequence (e.g., including the APP coding sequence).
[0081] Additional gene editing systems that can be used in the practice of the invention include TALENs (transcription activator-like effector nucleases), ZFNs (zinc finger nucleases), and base editing, as well as newly developed techniques such as homing endonucleases and meganucleases (MegN) (which target and cleave DNA sequences) and primed editing (which generate RNA templates for genetic modification).
[0082] III. Pharmaceutical Compositions and Administration The present invention also provides pharmaceutical or physiological compositions comprising an effective amount of one or more agents useful in the methods of the present invention, both in prophylactic and therapeutic applications. Such pharmaceutical or physiological compositions may also include one or more pharma- ceutical or physiologically acceptable non-medicinal ingredients or carriers. For example, one exemplary composition of the present invention comprises or consists essentially of one or more expression vectors encoding a CRISPR system (e.g., Cas9 nuclease or equivalent and one or two sgRNAs) plus one or more physiologically acceptable non-medicinal ingredients or carriers. Another exemplary composition of the present invention comprises or consists essentially of one or more expression vectors encoding one or more inhibitory oligonucleotides (e.g., small inhibitory RNA molecules, antisense DNA oligonucleotides, or antisense RNA oligonucleotides) plus one or more physiologically acceptable non-medicinal ingredients or carriers. The pharmaceutical compositions of the present invention are suitable for use in a variety of drug delivery systems. For suitable formulations for use in the present invention, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, PA, 17th ed. (1985). For a brief review of methods for drug delivery, see Langer, Science 249:1527-1533 (1990).
[0083] The pharmaceutical composition of the present invention can be administered by various routes, for example, orally, subcutaneously, transdermally, intramuscularly, intravenously, or intracranially.The preferred route of administration of the pharmaceutical composition is local delivery to the organ or tissue associated with the target disease of the recipient at a predetermined daily dose.The appropriate dose can be administered as a single daily dose, or as a divided dose that is presented at appropriate intervals, for example, as two, three, four or more subdoses per day.
[0084] In the preparation of pharmaceutical compositions containing one or more active agents of the present invention, inert pharma-ceutically acceptable carriers are also used.Generally, pharmaceutical carriers can be either solid or liquid.Solid form preparations include, for example, powders, tablets, dispersible granules, capsules, cachets, and suppositories.Solid carriers can be one or more substances that can also function as diluents, flavorings, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; they can also be encapsulating materials.
[0085] In powders, the carrier is generally a finely divided solid that is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
[0086] In preparing pharmaceutical compositions in the form of suppositories, a low melting wax, such as a mixture of fatty acid glycerides and cocoa butter, is first melted and the active ingredient is dispersed therein by, for example, stirring, The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify.
[0087] The powders and tablets preferably contain about 5% to about 70% by weight of the active ingredient. Suitable carriers include, for example, magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methylcellulose, sodium carboxymethylcellulose, low melting wax, and cocoa butter.
[0088] The pharmaceutical composition may include a formulation of the active agent(s) with an encapsulating material as a carrier resulting in a capsule, in which the agent(s) are surrounded by a carrier (with or without other carriers) such that the carrier binds to the agent(s). Similarly, cachets may also be included. Tablets, powders, cachets, and capsules may be used as solid dosage forms suitable for oral administration.
[0089] Liquid pharmaceutical compositions include, for example, solutions suitable for oral or parenteral administration, suspensions, and emulsions suitable for oral administration. Sterile solutions of the active ingredient(s) in water or in a solvent containing water, buffered water, saline, PBS, ethanol, or propylene glycol are examples of liquid compositions suitable for parenteral administration. The compositions may contain pharma- ceutically acceptable auxiliary substances, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents, and surfactants, as necessary, to approximate physiological conditions.
[0090] Sterilized solutions can be prepared by dissolving the active ingredient(s) in a desired solvent system and then passing the resulting solution through a membrane filter to sterilize it, or alternatively by dissolving the sterilized ingredient(s) in a previously sterilized solvent under sterile conditions. The resulting aqueous solutions can be packaged for use as is or can be lyophilized, with the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the preparation is usually 3-11, more preferably 5-9, most preferably 7-8.
[0091] Pharmaceutical compositions containing one or more active agents can be administered for preventive and / or therapeutic treatment. In therapeutic applications, the compositions are administered to patients already suffering from Alzheimer's disease in an amount sufficient to prevent, cure, reverse, or at least partially slow or stop the symptoms of the disease and its complications, such as the onset, progression, duration, and severity of the disease. The amount sufficient to achieve this is defined as a "therapeutically effective dose". The amount effective for this use depends on the severity of the disease, the weight and general condition of the patient, and the nature of the active agent(s).
[0092] In prophylactic applications, pharmaceutical compositions containing one or more active agents are administered to patients susceptible to or at risk of developing Alzheimer's disease in an amount sufficient to delay or inhibit the onset of symptoms. Such an amount is defined as a "prophylactically effective dose." In this use, the exact amount of active agent(s) again depends on the patient's health and weight, as well as the nature of the active agent(s).
[0093] Single or multiple administrations of the compositions can be carried out with dose levels and patterns selected by the treating physician. In any event, the pharmaceutical formulation should provide a sufficient amount of agent(s) to effectively suppress APP expression and Aβ plaque formation in the patient, either therapeutically or prophylactically.
[0094] IV. Therapeutic Applications Using Nucleic Acids A variety of disease conditions can be treated by therapeutic approaches that involve introducing into cells nucleic acids that encode one or more agents that disrupt the APP genomic sequence or that inhibit the mRNA encoded by the APP genomic sequence (such as antisense or miRNA, or Cas9 nuclease and sgRNA), such that the coding sequence is transcribed to produce a polypeptide or oligonucleotide agent in the cell. For a discussion of the application of gene therapy to the treatment of inherited and acquired diseases, see Miller Nature 357:455-460 (1992); and Mulligan Science 260:926-932 (1993).
[0095] A. Vectors for Gene Delivery For delivery to a cell or organism, a polynucleotide encoding one or more active agents may be incorporated into a vector. Examples of vectors used for such purposes include expression plasmids capable of directing the expression of a nucleic acid in a target cell. In other cases, the vector is a viral vector system in which the polynucleotide is incorporated into the viral genome and can be transduced into a target cell. In some embodiments, the coding polynucleotide may be operably linked to an expression control sequence capable of directing the expression of a polypeptide or oligonucleotide in a desired target host cell. In many cases, the coding sequence is transcribed under the control of a promoter and optionally at least one transcriptional enhancer element. Such a promoter may be essentially constitutive (i.e., always active for directing transcription of the coding sequence) or essentially inducible (i.e., active for directing transcription of the coding sequence in the presence of a specific signal), and is preferably a promoter that specifically directs transcription in a particular tissue type or cell type of the delivery target. For example, a neuronal cell-specific promoter is preferably used for a vector intended for delivery to an anatomical site in the central nervous system, such as the brain. Thus, expression of a polypeptide-based inhibitor or an oligonucleotide-based inhibitor may be achieved under appropriate conditions in a target cell.
[0096] B. Gene Delivery Systems Viral vector systems useful for expressing polypeptides or oligonucleotides that disrupt genomic sequences, including APP coding sequences, include, for example, naturally occurring or recombinant viral vector systems. Depending on the specific application, suitable viral vectors include replication-competent, replication-defective, and conditionally replicating viral vectors. For example, viral vectors can be derived from the genomes of human or bovine adenoviruses, vaccinia viruses, herpes viruses, adeno-associated viruses (AAV), minute virus of mice (MVM), HIV, Sindbis viruses, and retroviruses, including but not limited to Rous sarcoma virus and lentivirus, and MoMLV. Usually, the coding sequence of interest (e.g., coding for the polypeptide-based or oligonucleotide-based active agent of the present invention) is inserted into such vectors in a manner that allows packaging of the genetic construct, usually accompanied by viral DNA, followed by infection of susceptible host cells and expression of the coding sequence of interest.
[0097] As used herein, "gene delivery system" refers to any means for the delivery of a polynucleotide sequence of interest to a target cell. In some embodiments of the present invention, the nucleic acid is complexed to a cell receptor ligand for promoting uptake (e.g., coated pit invagination and endosomal internalization) via a suitable linking moiety, such as a DNA linking moiety (Wu et al., J. Biol. Chem. 263:14621-14624 (1988); WO92 / 06180), or by ultrasound-microbubble delivery system (Lan HY et al., J. Am Soc. Nephrol. 14:1535-1548). For example, the nucleic acid can be linked to asialo-oroorosomucoid, the hepatocyte asialoglycoprotein receptor ligand, via a polylysine moiety.
[0098] Similarly, the viral envelope used to package the genetic construct containing the nucleic acid of interest may be modified by the addition of a receptor ligand or a receptor-specific antibody to allow receptor-mediated endocytosis in certain cells (see, e.g., WO93 / 20221, WO93 / 14188, and WO94 / 06923). In some embodiments of the invention, the DNA construct of the invention is linked to a viral protein, such as an adenovirus particle, to facilitate endocytosis (Curiel et al., Proc. Natl. Acad. Sci. USA 88:8850-8854 (1991)). In other embodiments, active agents of the invention may include microtubule inhibitors (WO / 9406922), synthetic peptides that mimic influenza virus hemagglutinin (Plank et al., J. Biol. Chem. 269:12918-12924 (1994)), and nuclear localization signals such as SV40 T antigen (WO93 / 19768).
[0099] Retroviral vectors may also be useful for introducing the coding sequence of the polypeptide or oligonucleotide active agent of the present invention into target cells or tissues. Retroviral vectors are produced by genetically engineering retroviruses. The viral genome of retroviruses is RNA. Upon infection, this genomic RNA is reverse transcribed into a DNA copy, which is highly stable and efficiently integrated into the chromosomal DNA of the transduced cell. The integrated DNA copy is called a provirus and is inherited by daughter cells in the same way as any other gene. Wild-type retroviral genomes and proviral DNA contain three genes, the gag gene, the pol gene, and the env gene, which are flanked by two long terminal repeat (LTR) sequences. The gag gene codes for the internal structural (nucleocapsid) protein; the pol gene codes for the RNA-directed DNA polymerase (reverse transcriptase); and the env gene codes for the viral envelope glycoprotein. The 5'LTR and 3'LTR function to facilitate transcription and polyadenylation of the virion RNA. Adjacent to the 5'LTR are sequences required for reverse transcription of the genome (tRNA primer binding site) and efficient packaging of viral RNA into the particle (Psi site) (see Mulligan, In:Experimental Manipulation of Gene Expression, Inouye (ed), 155-173 (1983); Mann et al., Cell 33:153-159 (1983); Cone and Mulligan, Proceedings of the National Academy of Sciences, USA, 81:6349-6353 (1984)).
[0100] The design of retroviral vectors is well known to those skilled in the art. Briefly, when sequences required for encapsidation (or packaging of retroviral RNA into infectious virions) are absent from the viral genome, the result is a cis-acting defect that prevents encapsidation of the genomic RNA. However, the resulting mutation is still capable of directing the synthesis of all virion proteins. Retroviral genomes in which these sequences have been deleted, as well as cell lines containing mutant genomes stably integrated into chromosomes, are well known in the art and are used to construct retroviral vectors. The preparation and use of retroviral vectors has been described in many publications, including, for example, European Patent Application Publication EPA 0 178 220; U.S. Pat. No. 4,405,712; Gilboa Biotechniques 4:504-512 (1986); Mann et al., Cell 33:153-159 (1983); Cone and Mulligan Proc. Natl. Acad. Sci. USA 81:6349-6353 (1984); Eglitis et al. Biotechniques 6:608-614 (1988); Miller et al. Biotechniques 7:981-990 (1989); Miller (1992) supra; Mulligan (1993), supra; and WO 92 / 07943.
[0101] Retroviral vector particles are prepared by recombinantly inserting a desired nucleotide sequence into a retroviral vector and packaging the vector with retroviral capsid proteins by using a packaging cell line. The resulting retroviral vector particles are unable to replicate in the host cell but are capable of integrating into the genome of the host cell as a proviral sequence containing the desired nucleotide sequence. As a result, the patient is able to produce, for example, a polypeptide-based or polynucleotide-based active agent useful in the methods of the present invention, thus restoring the target cells (e.g., brain endothelial cells) to a normal phenotype.
[0102] The packaging cell lines used to prepare retroviral vector particles are usually recombinant mammalian tissue culture cell lines that produce the necessary viral structural proteins required for packaging but are incapable of producing infectious virions. The defective retroviral vectors used, on the other hand, are those that lack these structural genes but encode the remaining proteins required for packaging. To prepare the packaging cell lines, an infectious clone of the desired retrovirus can be constructed that lacks the packaging site. Cells containing this construct express all viral structural proteins but do not package the introduced DNA. Alternatively, packaging cell lines can be produced by transforming the cell line with one or more expression plasmids that code for the appropriate core and coat proteins. In these cells, the gag, pol, and env genes can be from the same or different retroviruses.
[0103] Several packaging cell lines suitable for the present invention are also available in the prior art. Examples of these cell lines include Crip, GPE86, PA317, and PG13 (see Miller et al., J. Virol. 65:2220-2224 (1991)). Other examples of packaging cell lines are described in Cone and Mulligan Proceedings of the National Academy of Sciences, USA, 81:6349-6353 (1984); Danos and Mulligan Proceedings of the National Academy of Sciences, USA, 85:6460-6464 (1988); Eglitis et al. (1988), supra; and Miller (1990), supra.
[0104] Packaging cell lines capable of producing retroviral vector particles having chimeric coat proteins may be used. Alternatively, amphotropic or xenotropic coat proteins, such as those produced by the PA317 and GPX packaging cell lines, may be used to package the retroviral vector.
[0105] C. Pharmaceutical Preparations When used for pharmaceutical purposes, the nucleic acid encoding the polypeptide or oligonucleotide active agent is generally formulated in an appropriate buffer, which can be any pharma- ceutically acceptable buffer, such as phosphate buffered saline or sodium phosphate / sodium sulfate, Tris buffer, glycine buffer, sterile water, and other buffers known to those of skill in the art, such as those described in Good et al. Biochemistry 5:467 (1966).
[0106] The composition may further comprise a stabilizer, enhancer, or other pharma- ceutically acceptable carrier or vehicle. Pharmaceutically acceptable carriers may include, for example, physiologically acceptable compounds that function to stabilize the nucleic acid of the present invention and any related vectors. Physiologically acceptable compounds may include, for example, carbohydrates such as glucose, sucrose, or dextran, antioxidants such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins, or other stabilizers or non-pharmaceutical ingredients. Other physiologically acceptable compounds include wetting agents, emulsifying agents, dispersing agents, or preservatives that are particularly useful for inhibiting the growth or action of microorganisms. Various preservatives are well known and include, for example, phenol and ascorbic acid. For examples of carriers, stabilizers, or adjuvants, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, PA, 17th ed. (1985).
[0107] D. Administration of Formulations Formulations containing polynucleotide sequences encoding polypeptide or oligonucleotide active agents can be delivered to target tissues or organs using any delivery method known to those skilled in the art. In some embodiments of the invention, the encoding polynucleotide sequences are formulated for subcutaneous, intramuscular, intravenous, or intraperitoneal injection, for oral ingestion / nasal inhalation, or for topical application.
[0108] The formulation containing the nucleic acid of interest is usually administered directly to the cell. The cell may be provided as an isolated cell, such as a red blood cell as part of the circulatory system, as part of a tissue, or in tissue culture. The cell may be provided in vivo, ex vivo, or in vitro.
[0109] The formulations can be introduced into the tissue of interest in vivo or ex vivo by a variety of methods. In some embodiments of the invention, the nucleic acid of interest is introduced into the cells by methods such as microinjection, calcium phosphate precipitation, liposome fusion, ultrasound, electroporation, or biolistics. In further embodiments, the nucleic acid is taken up directly by the target tissue or organ associated with the disease or condition being treated, for example, intracranial injection is appropriate when the target cells are endothelial cells of the brain.
[0110] In some embodiments of the invention, the nucleic acid of interest is administered ex vivo to cells or tissues explanted from a patient and then returned to the patient. Examples of ex vivo administration of therapeutic gene constructs include Nolta et al., Proc Natl. Acad. Sci. USA 93(6):2414-9 (1996); Koc et al., Seminars in Oncology 23(1):46-65 (1996); Raper et al., Annals of Surgery 223(2):116-26 (1996); Dalesandro et al., J. Thorac. Cardi. Surg., 11(2):416-22 (1996); and Makarov et al., Proc. Natl. Acad. Sci. USA 93(1):402-6 (1996).
[0111] The effective dosage of a formulation will vary depending on many different factors, including the means of administration, the target site, the physiological condition of the patient, and other drugs being administered. Thus, treatment dosages need to be titrated to optimize safety and efficacy. In determining the effective amount of vector to be administered, the physician should evaluate the specific nucleic acid used, the disease state being diagnosed; the patient's age, weight, and general condition, circulating plasma levels, toxicity of the vector, disease progression, and production of anti-vector antibodies. Dose size will also be determined by the presence, nature, and extent of any adverse side effects associated with administration of the specific vector. For example, an amount of 1-1000 mg, 10-200 mg, or 20-100 mg of antisense oligonucleotide may be delivered to a patient by intravenous injection at a frequency of weekly, biweekly, or monthly for at least one month to three months, or longer. For CRISPR editing targeting the APP genomic region, as another example, 5×10 5Cells (e.g., HEK293T cells or cells of neuronal origin) are transfected with 0.5-50 μg; 1-20 μg; or 2-10 μg of vector carrying a gene encoding Cas9 together with a pair of sgRNAs. For CRISPR editing targeting the APP genomic region in human patients, the dose of lipid nanoparticles carrying sgRNA and mRNA encoding Cas9 is in the range of 0.01-2 mg; 0.02-1.0 mg; 0.05-0.5 mg; or 0.10-0.30 mg per kg of body weight, delivered 1-3 times over a period of 1-4 weeks by iv injection.
[0112] V.Kit The invention also provides kits for treating amyloid pathologies (such as Alzheimer's disease) or reducing the risk of amyloid pathologies (such as Alzheimer's disease) in an individual in need thereof by the methods of the invention. The kits typically include a container that contains (1) a pharmaceutical composition having an effective amount of one or more active agents capable of disrupting a genomic sequence that includes an APP coding sequence and / or suppressing mRNA transcribed from said genomic sequence; and (2) informational material including instructions on how to prepare the pharmaceutical composition, including descriptions of the types of patients that may be treated (e.g., human patients suffering from or at risk for Alzheimer's disease), schedules (e.g., dosage and frequency), and routes of administration. In some cases, the kit comprises two or more containers for providing a plurality of pharmaceutical compositions, each of which comprises an effective amount of at least one active agent, such as a vector or vectors encoding a component of the CRISPR system (e.g., Cas9 nuclease or equivalent and one or more sgRNAs) or encoding an siRNA, microRNA, miniRNA, lncRNA, or antisense oligonucleotide that targets a genomic sequence that includes an APP coding sequence. Optionally, the kit further comprises one or more additional containers, each of which contains at least one agent that is useful for sequencing at least a portion of an individual's genome, in particular an APP genomic sequence that includes a subregion(s) of interest, for example, an APP genomic sequence that includes one or more sites of a known mutation, such as the Swedish mutation. EXAMPLES
[0113] The following examples are offered by way of illustration only, and not by way of limitation, as those of ordinary skill in the art will readily recognize a variety of non-critical parameters that could be changed or modified to yield essentially similar results.
[0114] Example 1: CRISPR-mediated disruption of APP targeting the Swedish mutation Familial Alzheimer's disease is caused by dominant mutations in the genes encoding amyloid precursor protein (APP), presenilin 1, and presenilin 2. Pathological hallmarks, including extracellular amyloid plaques and intracellular neurofibrillary tangles, are present in multiple brain regions. Targeting mutations with CRISPR / Cas9-mediated genome editing is a promising disease-modifying therapeutic approach, but brain-wide remission of Alzheimer's disease phenotypes has not been demonstrated using this approach. Here, we show that CRISPR / Cas9-mediated genome editing with a single administration of adeno-associated virus (AAV) efficiently and selectively disrupts mutant APP in a transgenic mouse model carrying the human APP Swedish mutation, resulting in the alleviation of amyloid beta-associated pathology for at least 6 months after injection. Importantly, intravenous delivery of modified AAV-Cas9 capable of crossing the blood-brain barrier reduces amyloid beta-associated brain pathology and cognitive impairment. Thus, our work on brain-wide gene editing provides a novel approach to the development of non-invasive, single-dose disease-modifying treatments for familial Alzheimer's disease and other monogenic diseases that affect multiple brain regions.
[0115] Introduction Alzheimer's disease (AD) is one of the most prevalent neurodegenerative disorders and is characterized by the presence of amyloid beta (Aβ) peptide deposits and neurofibrillary tangles composed of hyperphosphorylated tau protein. Hereditary forms of AD, called familial AD, account for 3-5% of AD cases. 1,2,3 , its prevalence is Huntington's disease 4 and amyotrophic lateral sclerosis 5 Familial AD is caused by fully penetrant autosomal dominant mutations in the genes encoding the amyloid precursor protein (APP) and presenilin 1 (PS1) and presenilin 2 (PS2), catalytic components of the γ-secretase complex. 2Dysregulation of APP processing by γ-secretase leads to the accumulation of Aβ peptides, which is a major factor in the pathogenesis of the disease. 6 Despite significant advances in our understanding of the genetic causes of familial AD, there are currently no effective disease-modifying treatments.
[0116] Clustered regularly interspaced short palindromic repeats (CRISPR) / Cas9-mediated genome editing is a powerful tool that can potentially target specific mutations 7 However, the development of CRISPR / Cas9 as a targeted genome editing approach for disease-modifying familial AD therapy will require addressing the need for widespread genome editing in the brain. Like most brain disorders, AD affects multiple brain regions, including the cortex and hippocampus. 8,9 Currently used genome editing tools for brain disorders are delivered by intraparenchymal injection. 10 However, they act on limited brain regions with limited beneficial outcomes. Therefore, there is an urgent need for efficient and comprehensive genome editing methods that can be used in the adult brain. Modified adeno-associated virus (AAV) variants that can cross the blood-brain barrier (BBB) have recently been developed, allowing widespread central nervous system transduction after intravenous delivery. 11、12、13、14 Accordingly, brain-wide overexpression of a BBB-crossing virally delivered protein has been shown to promote recovery after ischemic stroke in aged mice. 14 Therefore, altering the expression of disease-modifier gene(s) in the CNS by administration of BBB-crossing viruses has potential for development as a therapeutic approach for diseases such as familial AD. However, the ability of such viruses to deliver CRISPR / Cas9 genome editing components to ameliorate the disease phenotype has not yet been tested in vivo.
[0117] Considering that most cases of familial AD are caused by single gene mutations, CRISPR / Cas9-mediated genome editing has demonstrated the ability to disrupt or correct familial AD mutations and reduce Aβ production in vitro. 15,16 Most patients with familial AD have a heterozygous disease-causing mutation. 2 Humans who naturally carry one copy of APP, PSEN1, or PSEN2 do not exhibit overt neurological symptoms. 17,18 Therefore, disruption of disease-causing alleles in adult-stage familial AD patients is a rational and feasible disease-modifying treatment for familial AD. Among familial APP mutations, the APP Swedish type (APP swe ) mutations (KM670 / 671) are present in the sequence encoding the β-secretase cleavage site of APP, making the mutated APP more available for enzymatic cleavage, resulting in higher Aβ production. 19,20,21 Recent studies have demonstrated that APP in transgenic mice carrying APP mutations swe The feasibility of disrupting the mutation by genome editing has been reported, but the low genome editing efficiency of less than 3% has hindered evaluation of the potential disease-modifying effect of disrupting this mutation. 16 .
[0118] In this study, APP swe We show that AAV-mediated delivery of mutation-specific Cas9 and sgRNA into the adult hippocampus results in efficient genome editing and alleviates multiple Aβ-related pathologies in a transgenic mouse model of Aβ deposition. Remarkably, this CRISPR-mediated beneficial effect persists for at least 6 months in the transgenic mice. Furthermore, APP swe A single systemic administration of a BBB-crossing AAV-Cas9 vector targeting the mutation ameliorates Aβ pathology throughout the brain. Thus, our results demonstrate that single-dose systemic AAV is a promising approach for the development of disease-modifying therapeutic interventions for familial AD. Furthermore, such methods may be applicable to other central nervous system disorders that affect multiple brain regions and are caused by autosomal dominant mutations.
[0119] result CRISPR / Cas9-mediated genome editing of APP swe Allele-specific disruption First APP swe The two-base mutation (KM670 / 671NL) was targeted by designing two sgRNAs, SW1 and SW2, that locate the mutation site within the first eight nucleotides immediately adjacent to the protospacer adjacent motif (PAM) sequence (5'-NNGRRT-3') of Staphylococcus aureus Cas9 (SaCas9) (Fig. 1a). This region is thought to be the "seed sequence" region important for Cas9-sgRNA recognition and Cas9 nuclease activity. 22 Mismatches between the sgRNA and wild-type (WT) sequences present in the seed sequence are poorly tolerated by Cas9. 23 We predicted that SW1 and SW2 would distinguish mutant APP sequences from the WT sequence. The targeting specificity of sgRNAs was confirmed in HEK293T cells using the EGxxFP reporter system. 24 By expressing enhanced green fluorescent protein (GFP), both SW1 and SW2 expressed the EGxxFP-APP swe APP in Reporter swe The sequence was cut and EGxxFP-APP WT APP in Reporter WT It was shown that the sequence was not cleaved (Fig. 1c). swe This indicates that there was high allele specificity for the mutation. swe Considering that SW1 showed higher genome editing efficiency in the reporter and that SW1-mediated genome editing would disrupt the β-secretase cleavage site of APP, SW1 was selected for the subsequent genome editing experiments. The allele specificity of SW1 and SW2 suggested that they could be involved in the expression of APP WT To confirm that this was not due to an inability to edit the allele, we performed APP WTWe constructed two other sgRNAs, WT1 and WT2, that target the APP allele. The genome editing efficiency of WT1 and WT2 was over 50%, whereas neither SW1 nor SW2 could effectively target the APP allele. WT SW1 and SW2 did not induce observable genome editing in HEK293T cells carrying the APP allele (Fig. 8a, b). swe It was shown to specifically target the mutation. Furthermore, testing for potential off-target effects by T7 endonuclease I mismatch assay at the top five computationally predicted off-target sites showed no detectable off-target activity in HEK293T cells (Fig. 8c, d).
[0120] CRISPR / Cas9 system promotes APP expression in vivo swe To investigate its ability to disrupt the mutation, sgRNA SW1 was packaged into a single AAV9 vector, EFS::Cas9-SW1, with Cas9 driven by the elongation factor 1-alpha short (EFS) promoter, and the virus was injected into the hippocampus of 3-month-old 5XFAD mice (Fig. 1d). The 5XFAD mice harbor human APP cDNA with the K670N / M671L [Swedish], I716V [Florida], and V717I [London] mutations. CRISPR-mediated genome editing of the APP Swedish mutation abolishes the expression of full-length mutant APP, thus disrupting the effect of the APP mutation. Four weeks after injection, mouse brains were harvested for genomic analysis. AAV-mediated in vivo delivery of Cas9-SW1 virally transduced APP in brain regions. swe The mutation was efficiently edited (27% genome editing efficiency; Fig. 1e, f, and Fig. 8e) in the APP1 gene by AAV-mediated administration of Cas9-SW1. swe This suggests that the mutation was efficiently destroyed in vivo.
[0121] Potential off-target events induced by Cas9-SW1 genome editing were then investigated by performing whole genome sequencing. Similar numbers of mutations (approximately 35,000) were detected in both virally transduced and non-transduced regions of individual mouse brains (n=2; Fig. 8f and Table 1), suggesting that off-target events induced by Cas9-SW1 editing are rare. We subsequently identified 257 somatic mutations present in 46 genes as potential off-target events (Fig. 8g). Notably, we identified 17 genes characterized by 23 somatic mutations within exons or untranslated regions that may affect the regulation of gene expression and therefore function (Table 2). Notably, cell type-specific transcriptome analysis suggested that only three genes, namely Sp110, Sp140, and Abcg2, were expressed in mouse brains. 25 However, these three genes were not significantly expressed in neurons. 25 Therefore, the identified mutations are unlikely to affect biological function in the mouse brain.
[0122] Cas9-SW1 editing reduces amyloid plaque burden in 5XFAD mice APP in 5XFAD mice swe To test whether disruption of the mutation could reduce Aβ-associated pathology, we administered EFS::Cas9-SW1 to mice by AAV injection at a time when Aβ plaques were beginning to accumulate but had not caused obvious functional deficits. 26 We delivered 5XFAD-1000-mg DMSO into the hippocampus of 3-month-old 5XFAD mice. By 6 months, 5XFAD mice develop severe Aβ-related pathology characterized by elevated Aβ levels, Aβ plaque deposition, gliosis, and neuronal dysfunction (Figures 2-4). 26,27,28,29 Three months after Cas9-SW1-mediated gene editing, the contents of both diethylamine-extractable soluble Aβ and formic acid-extractable insoluble Aβ in the dorsal hippocampus region were reduced (Figure 2a), whereas the Aβ x-40 Species and Aβ x-42 The levels of both species were reduced by more than 60% (Fig. 2b, c).
[0123] We subsequently investigated whether AAV-mediated expression of Cas9-SW1 affected amyloid plaque deposition. Three months after injection of Cas9-SW1, 6-month-old 5XFAD mice showed significantly lower Aβ plaque burden in virally transduced hippocampal subregions when compared to the corresponding subregions in the uninjected side. Upon genome editing, Aβ-positive areas were reduced by 72.9% in the cornu ammonis (CA) region (Figure 2d, f, and Figure 9) and by 77.9% in the subiculum (Figure 2e, g, and Figure 9). Amyloid plaque burden remained low in 9-month-old 5XFAD mice (i.e., 6 months after injection); Aβ-positive areas were reduced by 74.3% in the CA region (Figure 2h, j, and Figure 9) and by 83.6% in the subiculum (Figure 2i, k, and Figure 9). These results demonstrate that the effect of Cas9-SW1-mediated editing on amyloid pathology persisted for at least 6 months after a single administration (Figures 2h-k and Figure 9).
[0124] Cas9-SW1 editing reduces gliosis in 5XFAD mice In 5XFAD mice, Aβ pathology is accompanied by gliosis, characterized by increased numbers of activated microglia and astrocytes surrounding amyloid plaques. 26 Therefore, we investigated whether the low amyloid plaque burden observed after genome editing in 5XFAD mice is associated with reduced gliosis. In the subiculum of 5XFAD mice, which show the most severe amyloid plaque deposition (Figure 9), AAV-mediated Cas9-SW1 editing led to reduced microgliosis and astrogliosis. Specifically, in 5XFAD mice, APP sweDisruption of the allele reduced the percentage of microglia labeled by ionized calcium-binding adaptor molecule 1 (Iba1) to 64.9% (Fig. 3a, b, and Fig. 10a). AAV-mediated Cas9-SW1 editing did not change the number of glial fibrillary acidic protein (GFAP)-positive astrocytes (Fig. 3c, d, and Fig. 10b), but a reduction in GFAP-positive areas was observed (Fig. 3c, e, and Fig. 10b). Collectively, these findings suggest that CRISPR / Cas9-mediated genome editing of the familial AD mutation led to reduced gliosis, as indicated by reduced microglial and reduced astrocyte activation, along with reduced Aβ levels and deposition.
[0125] Cas9-SW1 editing improves neurological function in 5XFAD mice To determine whether impaired hippocampal synaptic plasticity could be reversed in 5XFAD mice by a single injection of AAV-mediated Cas9-SW1, we measured the formation of long-term potentiation (LTP). Compared to WT mice, LTP at Schaffer collateral-CA1 synapses was significantly impaired in 6-month-old 5XFAD mice; AAV-mediated Cas9-SW1 editing reversed the reduction in LTP by 90% (Fig. 4a, b). Furthermore, we demonstrated that AAV-mediated Cas9-SW1 editing increased the number of excitatory synapses in the subiculum of 5XFAD mice by 43.9%, as revealed by co-staining for the presynaptic marker synaptophysin and the postsynaptic marker postsynaptic density 95 (PSD-95) (Fig. 4c-e). These results indicate that genome editing reduced synapse loss in transgenic mice.
[0126] Degenerated neurites, which are swollen neuritic processes present around amyloid plaques, also contribute to synaptic damage in AD. Specifically, aggregation of lysosomes in such neurites, which can be marked by the lysosomal protein LAMP1, alters axonal transport and synaptic release properties, resulting in disruption of synaptic connections. 30,31,32Accordingly, AAV-mediated Cas9-SW1 editing in 5XFAD mice reduced LAMP1-positive degenerated neurites by approximately 50% in the subiculum (Fig. 4f, h and Fig. S11) and increased the number of NeuN-positive neurons (Fig. 4g, i), suggesting that genome editing reduces neuronal loss.
[0127] Cas9-SW1 editing reduces Aβ pathology in APP / PS1 mice APP in transgenic mice with advanced disease states swe To test the efficacy of CRISPR-mediated disruption of the mutation, AAV-EFS::Cas9-SW1 was injected into the hippocampus of APP / PS1 mice, a transgenic mouse model of Aβ pathology that has a different time to onset of the disease phenotype compared to 5XFAD mice. In the APP / PS1 mouse model, Aβ plaque deposition and gliosis began to appear at approximately 4 months. 33,34 LTP impairment and cognitive impairment were observed at 6 and 12 months, respectively. 35,36 Therefore, AAV-EFS::Cas9-SW1 was injected at 9 months of age (when Aβ-related pathology and hippocampal synaptic dysfunction were well manifested) and brains were harvested 6 months later. Genome editing efficiency was 24% in APP / PS1 mice (Fig. 12a, b), which is comparable to the 27% observed in 5XFAD mice. Furthermore, after Cas9-SW1 administration, amyloid plaque burden was lower in the virally transduced hippocampal regions of APP / PS1 mice than in the non-transduced regions. Specifically, amyloid plaque burden in the CA and subiculum of APP / PS1 mice was reduced by 31.7% and 49.2%, respectively (Fig. 5a-d and Fig. 12c, d). Concomitant with the reduction in Aβ deposition, Cas9-SW1 editing reduced the number of Iba1-labeled microglia by nearly half (Fig. 5e, f). We also observed fewer GFAP-labeled astrocytes (Fig. 5g, h) and smaller GFAP-positive areas (Fig. 5g, i). Collectively, these results suggest that CRIPSR / Cas9-mediated genome editing reduced amyloid deposition and gliosis in transgenic mice with fully developed disease-associated phenotypes.
[0128] Systemic delivery of Cas9-SW1 globally reduces Aβ pathology in 5XFAD mice Considering that intrahippocampal injection of AAV-EFS::Cas9-SW1 reduced Aβ-associated pathology in the virally transduced area (Figures 2-4), we investigated the possibility of achieving Cas9-SW1-mediated genome editing in the whole brain. 11 The development of Cas9-SW1 enabled efficient systemic delivery of Cas9-SW1 to the adult brain. Therefore, we created a BBB-penetrating AAV-Cas9 vector driven by the neuron-specific human synapsin 1 (Syn) promoter SW1-Syn::Cas9 (Figure 13a). Given that systemic administration of this AAV vector only resulted in limited expression of Cas9 in the mouse brain (Figure 13b), we created a viral construct that would result in enhanced expression of Cas9 in vivo. Specifically, we engineered a truncated woodchuck hepatitis virus (WHP) posttranscriptional regulatory element (WPRE) 37 Insertion of this gene into an AAV construct (SW1-Syn::Cas9-mWPRE; Fig. 6a) dramatically increased Cas9 expression in the hippocampus and cortex; the size of this construct remained within the ~5 kb packaging capacity of AAV. 38 Through such optimization, this novel BBB-penetrating neuron-specific genome editing system achieved genome editing efficiency in the brain equivalent to that achieved by intrahippocampal injection (Fig. S14a, b).
[0129] Systemic delivery of Cas9-SW1 to 5XFAD mice by AAV-PHP.eB resulted in widespread expression of HA-tagged Cas9 throughout the brain (Fig. 14c) and reduced amyloid plaque deposition in various brain regions (Fig. 6b-d). Notably, amyloid plaque burden was reduced not only in the CA and subiculum of the hippocampus (Fig. 6e-h and Fig. 14d), but also in other brain regions, including the cortex (Fig. 6i, k) and medulla oblongata of the brainstem (Fig. 6j, l and Fig. 14c). Meanwhile, systemic injection of Cas9 with a scrambled sgRNA (i.e., AAV-PHP.eB:Con-Syn::Cas9-mWPRE) as a control did not cause obvious adverse effects in either WT or 5XFAD mice. Specifically, the control virus did not induce gliosis or behavioral deficits in WT mice (Fig. 15a-f). Furthermore, control virus had no effect on amyloid plaque burden in 5XFAD mice (Figure 15g-i). Thus, collectively, our results demonstrate that systemic administration of Cas9-SW1 reduced Aβ pathology in multiple brain regions of 5XFAD mice.
[0130] Systemic delivery of Cas9-SW1 reduces microgliosis and neurite degeneration and improves cognitive performance in 5XFAD mice After systemic Cas9-SW1 editing, 5XFAD mice showed reduced Iba1-labeled microglia (Fig. 7a, b) and LAMP1-positive degenerated neurites (Fig. 7d, e) in the subiculum, suggesting that systemic delivery of Cas9-SW1 globally reduces Aβ-associated phenotypes, including microgliosis and neurite degeneration, in 5XFAD mice.
[0131] Previous studies have reported that Aβ transgenic mouse models exhibit impaired habituation and working memory, as well as increased risk-taking behavior. 26,35,39,40Given that systemic delivery of Cas9-SW1 globally reduced amyloid-related pathology, its beneficial effects on habituation ability, working memory, and risk-taking behavior in 5XFAD mice were assessed by using the open-field exploration test, Y-maze spontaneous alternation test, and elevated plus-maze test, respectively. In the open field test, 5XFAD mice showed significantly slower habituation to the novel test environment than WT mice during the 3-day training course. In contrast to uninjected 5XFAD mice, mice administered Cas9-SW1 showed significantly improved habituation to the test environment (Figure 7e).
[0132] The Y-maze test measures the working memory of mice by having them explore the three arms of a maze. Intact working memory (to remember which arm they had previously visited) is required for mice to be able to alternate between entering and leaving the arm. Compared with WT mice, 5XFAD mice showed a significantly lower percentage of spontaneous alternations in total entries (Fig. 7f). Meanwhile, 5XFAD mice administered Cas9-SW1 showed a significantly higher percentage of spontaneous alternations than mice not administered Cas9-SW1 (Fig. 7f).
[0133] On the other hand, the elevated plus maze test examines risk-taking behavior and exploratory motivation in mice by assessing exploration of an anxiety-inducing open area. 39,40 Although 5XFAD mice spent more time in the open arms than WT mice, 5XFAD mice administered Cas9-SW1 spent significantly less time in the open arms compared to uninjected 5XFAD mice (Figure 7g). Collectively, these results suggest that systemic delivery of Cas9-SW1 improved the cognitive performance of 5XFAD mice.
[0134] Consideration In this study, we demonstrated that a single injection of an AAV-Cas9 vector can induce the expression of human APP sweWe demonstrate that the allele was selectively and efficiently edited in vivo and ameliorated Aβ-associated pathology in an Aβ deposition transgenic mouse model. 11 Utilizing this systemic administration of the CRISPR / Cas9 system in transgenic mice achieved efficient genome editing in multiple brain regions, exerting global beneficial effects, ameliorating Aβ deposition, microgliosis, and neurite degeneration, and improving cognitive function. To the best of our knowledge, this is the first demonstration of systemic AAV delivery targeting disease-causing mutations at the adult stage, resulting in efficient brain-wide genome editing and resulting in alleviation of disease phenotypes throughout the brain.
[0135] Among familial AD mutations, APP swe The mutations are double point mutations present within the "seed sequence" of SaCas9 that allow for selective target recognition; and because this allows mismatches between the sgRNA and genomic DNA within the "seed sequence" region to be poorly tolerated by the Cas9 nuclease. 22 , making them ideal candidates for allele-specific editing. swe Selective disruption of mutant alleles of APP1 and APP2, respectively, in the hippocampus of a transgenic mouse model of Aβ deposition swe This was achieved by using two AAVs expressing specific sgRNA and the Cas9 nuclease of Streptococcus pyogenes (SpCas9, 1,368 amino acids), but the genome editing rate of this CRISPR / Cas9 system for familial AD mutant alleles was less than 3%. 16 Therefore, to increase the efficiency of Cas9 editing, two vectors in the case of SpCas9 were used. 41 Instead, we utilized the CRISPR / Cas9 system, which can be packaged into an all-in-one AAV vector with the smaller SaCas9 (1,053 amino acids) and its sgRNA. Thus, we succeeded in improving the in vivo editing efficiency of the CRISPR / Cas9 system to about 30%. sweAlthough mutated in only a minority of cases, other familial AD mutations, such as PSEN1 L166P, are also amenable to allele-specific gene disruption. Over 200 disease-causing dominant mutations in APP, PSEN1, and PSEN2 have been identified to date. 42 Furthermore, the development of SaCas9 variants with alternative PAM compatibility 43 This expands the targeting scope of the CRISPR / Cas9 system, thereby broadening the range of candidate nucleotide sequences for familial AD mutations that can be targeted for allele-specific disruption. Although familial AD accounts for only approximately 3-5% of all AD cases, 1,2,3 However, this CRISPR / Cas9-mediated genetic approach still holds immense potential for the development of therapeutics for familial AD.
[0136] Two recent studies have demonstrated that CRISPR / Cas9-based approaches can ameliorate Aβ-related phenotypes in transgenic mouse models, but translating these to the clinic may be challenging. In one study, using the CRISPR / Cas9 system to reduce APP expression in the germline of APP knock-in mice alleviated amyloid plaque burden. 44 However, it remains to be seen whether germline editing can be translated into an intervention for AD. Another study used CRISPR / Cas9-mediated genome editing to knock out β-secretase 1 (BACE1) in the hippocampus of adult transgenic mice to alleviate Aβ-related pathology. 45 However, BACE1 is not a good target for clinical applications because its inhibition can cause deleterious effects, such as impaired synaptic function and cognitive behavior. 46,47,48 In this study, APP swe We show that CRISPR / Cas9-mediated disruption of the allele ameliorates not only amyloid plaque deposition but also gliosis, synaptic dysfunction, and cognitive impairment in an Aβ deposition transgenic mouse model. Thus, disruption of the disease-causing allele in adult-stage familial AD patients is a promising disease-modifying approach for familial AD.
[0137] Our study also effectively addresses one of the major challenges of developing a CRISPR / Cas9 system for the treatment of AD: the need for brain-wide genome editing. Although AD affects multiple brain regions, currently used delivery methods into the adult brain (both viral and non-viral) require intraparenchymal injection. 10 , which limits the region of Cas9 editing. Single-site intrahippocampal injection of AAV9 infects only a portion of the hippocampus. Thus, insufficient delivery of the CRISPR / Cas9 system may negate its potential beneficial effects. Therefore, efficient brain-wide delivery of genome editing components is urgently needed for therapeutic development of the CRISPR / Cas9 system for familial AD. AAV-PHP.eB 11 A BBB-passing virus was modified to carry the CRISPR / Cas9 system and edited the APP gene in vivo. Importantly, because Aβ is primarily produced by APP-expressing neurons, a neuron-specific promoter was used to drive the expression of Cas9 for neuron-specific genome editing. This system only disrupts mutant APP in neurons, which reduces potential safety concerns caused by Cas9 editing since postmitotic neurons cannot divide. By optimizing the Cas9 expression construct (i.e., inserting a truncated WPRE element into the AAV vector construct to enhance Cas9 expression), our PHP.eB-mediated CRISPR / Cas9 system achieved global editing rates in the brain comparable to those achieved by local intrahippocampal injection. Although AAV-PHP.eB is restricted to certain strains of mice, new engineered vectors have been developed that can transduce previously resistant strains such as BALB / c, and other species such as marmosets. 49,50 Given these ongoing developments, our study is a proof-of-concept for genome editing therapy using a systemically delivered vector.
[0138] To enhance the therapeutic development of CRISPR-mediated genome editing, it is important to evaluate potential off-target events induced by genome editing. Herein, comparison of whole genome sequencing data of virally transduced and non-transduced brain regions in individual animals suggested that off-target events induced by Cas9-SW1 editing were rare, as the number of mutations in virally transduced regions was close to the basal number in non-transduced regions. After prioritizing mutations according to their genomic location and the brain expression of the corresponding genes, we narrowed down the potential off-target events of Cas9-SW1 to three genes that are expressed in the brain and whose expression levels would be affected: Sp110, Sp140, and Abcg2. Notably, Sp110 and Sp140 belong to the nucleolar protein family and potentially regulate gene transcription. 51 On the other hand, Abcg2 belongs to the ATP-binding cassette (ABC) transporter superfamily and functions as a xenobiotic export transporter. 52 Notably, these genes are not significantly expressed in neurons. 25 Because the synapsin-driven Cas9 system can only target neurons, these mutations are unlikely to affect the expression and therefore function of these genes in neurons. Therefore, the biological effects of these potential off-target mutations are likely to be minimal. Furthermore, our findings highlight the importance of unbiased and comprehensive analysis of potential off-target events for the development of CRISPR / Cas9-mediated gene therapy, such as whole genome sequencing.
[0139] In summary, we have applied a BBB-crossing AAV-mediated CRISPR / Cas9-based approach to selectively and efficiently edit disease-causing alleles in vivo. Our proof-of-concept study demonstrated that mutant APP sweWe demonstrate that brain-wide editing of alleles resulted in durable beneficial effects in vivo, including mitigation of Aβ-related pathology, making it a promising avenue for further development. Thus, our AAV-mediated, single-dose, non-invasive CRISPR / Cas9 system is a promising approach to address the lack of therapeutic options for familial AD, as well as other forms of brain disease caused by dominant mutations affecting multiple brain regions.
[0140] method Molecular cloning and GFP reporter assay pX601-AAV-CMV::NLS-SaCas9-NLS-3xHA-bGHpA;U6::BsaI-sgRNA(Zhang Lab;Addgene plasmid #61591) 41 The AAV packaging construct derived from was adapted. For intrahippocampal injection, the cytomegalovirus (CMV) promoter was replaced with the promoter of EFS. For systemic injection, the promoter was replaced with the human synapsin 1 (hSyn) gene promoter and a truncated WPRE cassette (Addgene plasmid #61463) was added to enhance Cas9 expression. 37 A modified pX601 construct was used. Additionally, bovine growth hormone (BGH) polyA was replaced with synthetic poly(A) (spA). sgRNA was inserted into the construct via the BsaI site. The sequence of the sgRNA is shown in Table 3.
[0141] GFP reporter construct pCAG-EGxxFP (Addgene plasmid #50716) 24 was kindly provided by Masahito Ikawa and evaluated the genome editing efficiency of Cas9-sgRNA. swe Alleles and APP WTThe allele was inserted into the BamHI and EcoRI sites by oligo ligation. 1 μg of Cas9-sgRNA was mixed with 1 μg of pCAG-EGxFP-APP, and the mixture was transfected into HEK293T cells using Lipofectamine 3000 (Thermo Fisher Scientific). 12 hours after transfection, the resulting GFP expression was examined by fluorescence microscopy.
[0142] mouse 5XFAD transgenic mice carrying five familial AD mutations (APP K670N / M671L [Swedish type], I716V [Florida type], V717I [London type], and PSEN1 M146L and L286V) 26 , and APP / PS1 transgenic mice carrying the APP K670N / M671L (Swedish) mutation and a PSEN1 exon 9 deletion 33 were obtained from Jackson Laboratory (stock numbers 008730 and 004462, respectively). All experiments were performed using male 5XFAD mice or female APP / PS1 mice. All mice were housed in the Animal and Plant Care Facility of the Hong Kong University of Science and Technology. All animal experiments were approved by the Animal Ethics Committee of the Hong Kong University of Science and Technology.
[0143] Intrahippocampal and systemic injection of AAV For AAV used for intrahippocampal injection, AAV9-Cas9-SW1 was generated by the University of North Carolina at Chapel Hill Vector Core and titered by dot blot. Three-month-old mice were anesthetized with isoflurane and 6 × 10 per animal were injected. 10 3 x 10 vector genome (vg) virus in 2 µL 13 The following coordinates (relative to bregma): anterior-posterior (AP), -2.0 mm; mediolateral (ML), -1.7 mm; dorsoventral (DV), -1.4 mm were used to target the CA1 region of the hippocampus. 53 Intrahippocampal injection of empty AAV9 vectors does not produce adverse effects in mice54,55,56 Considering this, the uninjected side of the same mice was used as a control. Mice were sacrificed 3 or 6 months after virus injection.
[0144] Regarding AAVs used for systemic delivery, AAV-PHP.eB:Cas9-Con and AAV-PHP.eB:Cas9-SW1 have been reported. 57 The virus was prepared as described in 2011-01-11 and titered by quantitative polymerase chain reaction (qPCR). Three-month-old mice were anesthetized and infected with 1 × 10 13 vg / animal (1 × 10 in 100 μL) 14 Mice were sacrificed at 6 or 9 months of age and analyzed for Aβ-related pathology.
[0145] T7 endonuclease I assay A T7 endonuclease I mismatch assay was performed to analyze the editing efficiency. Briefly, the subiculum and cornu ammonis regions were dissected from 300 μm-thick hippocampal slices, and genomic DNA was extracted using QuickExtract DNA Extraction Solution (Epicentre Biotechnologies, QE09050). The amplified DNA was denatured and reannealed from 95°C to room temperature. Then, T7 endonuclease I (New England Biolabs, M0302) was added, and the mixture was incubated at 37°C for 15 minutes. The products were analyzed by visualization on 2.5% agarose gel electrophoresis. Then, the intensity of the enzyme-cut bands and the enzyme-uncut bands were quantified using ImageJ (NIH) software. Finally, the editing efficiency was calculated as follows:
number
[0146] Genome sequencing and bioinformatics analysis Genomic DNA was extracted using the EZNA Tissue DNA Kit (Omega Bio-tek) and subjected to Illumina NovaSeq (Novogene) for whole genome sequencing (50×). Raw reads (150 bp paired-end) were subjected to Trimmomatic (version 0.32) for trimming and filtering of low-quality reads. Reads that passed quality control were mapped to a modified version of the mouse reference genome (UCSC mm10) that additionally contains sequences of human APP and PSEN1 using BWA mem (version 0.7.12-r1039). Germline and somatic mutations were genotyped using default settings according to Genome Analysis Toolkit (GATK) Best Practices (version 4.1.2.0). Specifically, PCR duplicate reads were marked during BAM file processing and Base Quality Score Recalibration (BQSR) was performed. The final BAM file obtained by merging reads from multiple lanes was subjected to variant calling. Germline and somatic mutations were detected using HaplotypeCaller (version 4.1.2.0) and MuTect2 (version 4.1.2.0), respectively.
[0147] We hypothesized that genome editing may have potentially induced mutations in the virally transduced regions of both mice that were not detected in the non-transduced regions of either mouse. To detect germline mutations, we included genomic variants detected in 18 mouse strains. 58Base Quality Score Recalibration (BQSR) was applied using single nucleotide polymorphism (SNP) calls and insertion / deletion (INDEL) calls from the Mouse Genome Project, version 3. The frequency of editing events at the corresponding sites in each genomic DNA sample was estimated based on the number of reads of modified and unmodified alleles stored in the VCF file. R programming (R studio; version 1.3.1056) was used to filter mutations present within repetitive elements (UCSC repeatmasker mm10) and mutations overlapping with germline mutations. The presence of gene variants in the gene body of the Ensemble database from the BioMart database (http: / / asia.ensembl.org / biomart) was annotated. In addition, somatic mutations present in exons and untranslated regions were designed. Subsequently, the expression levels of the relevant genes in brain cells were analyzed using cell type-specific transcriptome datasets (Brain RNA-Seq). 25 Genes were considered expressed in the brain if they had an FPKM >1 in at least one brain cell type.
[0148] Aβ extraction, Western blot analysis, and ELISA Aβ peptides were extracted sequentially from the soluble and insoluble fractions of the dorsal hippocampus. 35 First, frozen hippocampal tissues were homogenized in tissue homogenization buffer (20 mM Tris HCl [pH 7.4], 250 mM sucrose, 1 mM EDTA, and 1 mM EGTA) containing a protease inhibitor cocktail (Sigma-Aldrich). Sequentially, soluble and insoluble Aβ were extracted by using diethylamine and formic acid, respectively. The levels of soluble and insoluble Aβ were analyzed by Western blot analysis. Furthermore, soluble Aβ was not detected by ELISA. x-40 and Aβ x-42 was analyzed by using the V-PLEX Aβ Peptide Panel 1 (6E10) Kit (Meso Scale Discovery).
[0149] immunohistochemistry Mice were anesthetized with pentobarbital and perfused transcardially with Dulbecco's PBS (DPBS). Mouse brains were dissected, post-fixed in 4% paraformaldehyde, and sectioned into 30 μm sagittal brain slides for immunohistochemistry using a free-floating vibratome (VT1000S, Leica). For 4G8 immunostaining, antigen retrieval was performed with 70% formic acid. Brain sections were then washed three times with DPBS and lysed with 2% goat serum and 0.3% Triton X-100 in DPBS. 59 Blocking was performed for 60 min at room temperature, followed by incubation with primary antibody overnight at 4°C.
[0150] The following primary antibodies were used: anti-HA tag (1:50; #3724, Cell Signaling Technology); anti-Aβ, 17-24 (1:1,000, clone 4G8, 800701, BioLegend); anti-Iba1 (1:500, 019-19741, Wako); anti-GFAP (1:5,000, #3670, Cell Signaling Technology); anti-PSD-95 (1:500, ab2723, Abcam); anti-synaptophysin 1 (1:500, 101011, Synaptic Systems); anti-LAMP-1 (1:500, 1D4B, Developmental Studies Hybridoma Bank); and anti-NeuN (1:100, MAB377, Millipore).
[0151] After the sections were incubated with the primary antibodies, they were washed three times with DPBS and 0.3% Triton X-100 (DPBST). The sections were then incubated with the secondary antibodies (i.e., anti-rabbit, anti-mouse, or anti-rat Alexa Fluor 488, 546, 568, or 647; Thermo Fisher Scientific) in blocking buffer for 120 min at room temperature. After application of the corresponding secondary antibodies, the brain sections were stained with a nuclear staining dye (4',6-diamidin-2-phenylindole [DAPI, 5 μg / mL] or SYTOX Green [1:30,000, S7020, Thermo Fisher Scientific]) and then mounted on slides.
[0152] For amyloid plaque staining with X34, brain sections were incubated in X34 staining buffer (40% ethanol / 60% DPBS mix [pH adjusted to 10]) containing 1 μM X34 for 10 min at room temperature, then washed three times with X34 staining buffer. 60 .
[0153] Imaging was performed using a Leica DM6000 B compound microscope system and a Leica TCS SP8 confocal system.
[0154] Electrophysiology Mice were sacrificed, the brains were dissected, and the brains were immediately transferred to ice-cold oxygenated (95% O) 0.5% CO. 2 / 5%CO 2 ) and transferred to artificial cerebrospinal fluid buffer. Subsequently, 300 μm brain slices were prepared using a vibratome (HM650V; Thermo Fisher Scientific) and allowed to recover in artificial cerebrospinal fluid for at least 1 h at 32 °C. CA1 field excitatory postsynaptic potentials (fEPSPs) were recorded by using a MED-P210A probe (Panasonic International) with an interelectrode distance of 100 μm. After a 30-min baseline recording, LTP was induced by four-pulse theta burst stimulation (10 short bursts of four pulses at 100 Hz). 61,62fEPSPs were recorded for 60 min. Finally, the magnitude of LTP was quantified as the percentage change in the mean slope of fEPSPs from 50 to 60 min after LTP induction.
[0155] Behavioral testing For the behavioral testing of the animals, the mice were subjected to the open field test and the Y-maze spontaneous alternation test, then rested for 2 months, and finally subjected to the elevated plus maze test.
[0156] In the open field test, locomotor activity of mice was recorded using a photobeam activity system and software (San Diego Instruments). 35 Each mouse was placed in the center of an open-top chamber (41 × 41 × 38 cm) and allowed to explore the chamber for 15 min each day for three consecutive days. The distance traveled was recorded by a photobeam.
[0157] The spontaneous alternation Y-maze test examines the spontaneous alternation ability of mice using a symmetric Y-maze (30 cm length × 20 cm height × 8 cm width). 63 One day before testing, each mouse was habituated to the Y-maze environment. On the day of testing, each mouse was placed in the center of the Y-maze and allowed to explore for 8 min. The order of the entered arms and the total number of arm entries were recorded using EthoVision XT7 (Noldus). The percentage of alternation behavior was calculated by dividing the number of consecutive entries into all three arms by the total number of arm entries minus 2. Re-entries into the same arm were not counted in the analysis.
[0158] Finally, in the elevated plus maze test, risk-taking behavior is measured using a plus-shaped maze elevated 60 cm above the floor. Four arms (30 cm long × 5 cm wide) extend from a central platform, including two open arms and two closed arms with 15 cm high walls. Each mouse was placed on the central platform facing the open arms and allowed to freely explore the maze for 5 min. 39The time that mice spent in each zone (i.e., closed arms, open arms, or center area) was recorded using an EthoVision XT7 (Noldus).
[0159] statistical analysis All data are presented as mean ± SEM, with n values indicating the number of individual experiments or mice. All statistical analyses were performed using GraphPad Prism (version 6.01). The significance of differences was assessed by paired two-tailed Student's t test or unpaired two-tailed Student's t test and two-way repeated measures ANOVA as indicated in the figure legends. Intrahippocampal injections were analyzed using paired two-tailed t test, as comparisons were between uninjected and injected sides of the hippocampus of a single mouse. Two-way repeated measures ANOVA was performed to analyze habituation in the open field test as group comparisons; otherwise unpaired two-tailed t test was performed. Differences between groups were evaluated using * P < 0.05, ** P < 0.01, and *** P<0.001 was considered statistically significant. No statistical methods were used to predetermine sample size. Mice were randomly assigned to the different experimental groups. The investigators performing the immunohistochemical, electrophysiological, and behavioral tests were blinded to the genotype and injection conditions of the mice. [Table 1] [Table 2] [Table 3]
[0160] Example 2: Destruction of APP by targeting the β- and γ-secretase cleavage sites Introduction Alzheimer's disease (AD) is one of the most prevalent neurodegenerative diseases and is characterized by the deposition of amyloid beta (Aβ) peptides and the presence of neurofibrillary tangles composed of hyperphosphorylated Tau protein. APP (amyloid precursor protein) is the precursor protein of Aβ, one of the hallmarks of AD. Missense mutations or copy number duplications in the APP gene are sufficient to cause early-onset AD. Aβ is mainly produced when APP is cleaved in neurons. Therefore, reducing the APP gene could reduce the production of Aβ and could be a potential therapy for the treatment of AD. APP has a physiological role in neural development, including neuronal migration and synaptic plasticity. Therefore, neuron-specific modulation of APP at the adult stage could be a beneficial approach to treat AD with minimal adverse effects.
[0161] APP is the precursor protein of Aβ, the main component of amyloid plaques. APP can undergo amyloidogenic and nonamyloidogenic proteolytic pathways. In the amyloidogenic pathway, APP is first cleaved by β-secretase to form a soluble secreted form of APP (sAPPβ) and a C-terminal fragment (βAPP-CTF). βAPP-CTF is sequentially cleaved by γ-secretase, resulting in the production of Aβ peptides of various lengths, including the APP intracellular domain (AICD) and the synaptic toxic 40-residue peptide (Aβ1-40) and 42-residue peptide (Aβ1-42). The nonamyloidogenic pathway, i.e., α-secretase-mediated cleavage pathway, inhibits the production of Aβ. In this pathway, cleavage of APP by α-secretase is within the Aβ sequence, thereby suppressing Aβ formation.
[0162] Most familial AD-causing mutations cluster at or near the α-, β-, and γ-secretase cleavage sites, promoting Aβ formation by favoring proteolytic processing of APP by β- and γ-secretase, thereby increasing total Aβ levels or Aβ 42 This leads to increased levels of Aβ, promoting the self-aggregation of Aβ into amyloid plaques. Therefore, disrupting the β-secretase and γ-secretase cleavage sites of APP can inhibit the amyloidogenic proteolytic pathway of APP and suppress the production of toxic Aβ. Microbial clustered regularly interspaced short palindromic repeats (CRISPR) / Cas9-mediated genome editing is a powerful tool to disrupt the genomic sequences encoding both β-secretase and γ-secretase, and has great potential for the treatment of AD.
[0163] In the present invention, single guide RNAs (sgRNAs) for specifically targeting exons 14-17 of the APP gene were designed with a neuron-specific promoter (Table C) (Figure 16 and Tables A, B), and the editing effect was analyzed in vitro (Figure 17). Compared with targeting a specific mutation site (i.e., APP Swedish mutation), CRSIPR / Cas9-mediated deletion of the β-secretase cleavage site of APP can be used to reduce APP expression in wild-type APP, as well as APP with most familial APP mutations (Figure 18, Table D). Therefore, this approach can be developed for the treatment of most familial AD cases. We demonstrated that CRSIPR / Cas9-mediated deletion of the β-secretase cleavage site of APP significantly reduced Aβ secretion (Figure 18). Such data collectively indicate that targeting the β-secretase and γ-secretase cleavage sites of APP is a feasible approach to reduce Aβ production and may be applicable to the treatment of most patients with familial AD mutations.
[0164] method Plasmids The sgRNA was inserted via the BsaI site (New England Biolabs) within AAV-EFS::NLS-SaCas9-NLS-3xHA-bGHpA;U6::sgRNA. The ligation product was then transformed into NEB Stable Competent E. coli (New England Biolabs) for molecular cloning. Plasmid DNA was prepared using the EZNA Plasmid DNA Mini Kit I (Omega Bio-tek) according to the manufacturer's instructions, and large-scale plasmids were prepared using the Qiagen Plasmid Maxi Kit (Qiagen) under endotoxin-free conditions.
[0165] cell culture HEK293T cells were incubated in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) containing 10% heat-inactivated fetal bovine serum (v / v, GIBCO) + 1% penicillin / streptomycin. HEK293T cells were transfected with Lipofectamine 3000 Reagent (Thermo Fisher Scientific) according to the manufacturer's instructions. Cells were harvested 48 hours after transfection, and the medium and cell pellets were collected.
[0166] Genomic DNA extraction and PCR amplification Genomic DNA was extracted from cell pellets using QuickExtract® DNA Extraction Solution (Lucigen) according to the manufacturer's instructions. KAPA HiFi HotStart ReadyMix (Roche) was used to amplify genomic DNA from 293T cells co-transfected with gRNA / Cas9 and pcDNA3-APP plasmids. PCR amplification consisted of denaturation at 98°C for 30 s, followed by 30 cycles of (98°C for 20 s, 65°C for 20 s, and 72°C for 30 s); and a final extension cycle of 72°C for 2 min.
[0167] T7 endonuclease I assay A T7 endonuclease I mismatch assay was performed to analyze the editing efficiency. T7 endonuclease I (New England Biolabs, M0302) was added to the PCR product, and the mixture was incubated at 37°C for 15 minutes. The products were analyzed by visualization on 2.5% agarose gel electrophoresis. Then, the intensity of the enzyme-cut bands and the enzyme-uncut bands were quantified using ImageJ (NIH) software. Finally, the editing efficiency was calculated as follows:
number
[0168] Quantification of secreted Aβ Secreted Aβ was quantified using MSD Human (6E10) Abeta3-Plex Kits (Meso Scale Discovery) according to the manufacturer's instructions. Secreted Aβ levels were normalized to total protein levels measured by BCA assay (Thermo Fisher Scientific). [Table 4] [Table 5-1] [Table 5-2] [Table 6] [Table 7-1] [Table 7-2]
[0169] Consideration In this study, amyloid beta production is first reduced by disrupting the cleavage sites in APP involved in the amyloidogenic proteolytic pathway. Disabling the β-secretase and γ-secretase cleavage sites in APP (amyloid precursor protein) leads to reduced production of amyloid beta (Aβ), one of the hallmarks of Alzheimer's disease (AD). This approach can be generally applied to any familial AD case with mutations in APP, PSEN1, and PSEN2, as well as to individuals with sporadic AD, which is associated with increased production of Aβ.
[0170] APP expression is manipulated at adult stage.APP has physiological roles in animal development; for example, in neuronal migration and synaptic plasticity.Therefore, specific manipulation of APP expression in the brain at adult stage shows beneficial outcomes and reduces potential side effects (due to off-target effects of genome editing tools).
[0171] Neuron-specific or neuron subtype-specific manipulation of APP is performed. Aβ is produced by cleavage of APP in neurons. Therefore, specific manipulation of APP expression in neurons by promoter-specific driven genome editing could avoid potential off-target effects occurring in other cell types. Furthermore, genome editing can be performed to reduce or eliminate any potential side effects in specific neuron subpopulations (i.e., inhibitory neurons, excitatory neurons).
[0172] The effects of genome editing throughout the brain are examined. Non-invasive delivery of genome editing components is achieved via intravenous administration. Whole genome sequencing is performed to demonstrate that Cas9-sgRNA does not introduce off-target events.
[0173] All patents, patent applications, and other publications, including GenBank accession numbers, cited in this application are hereby incorporated by reference in their entirety for all purposes.
[0174] References 1. Cai, Y., An, SS & Kim, S. Mutations in presenilin 2 and its implications in Alzheimer's disease and other dementia-associated disorders. Clinical interventions in aging 10, 1163-1172 (2015). 2. Campion, D., et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. American journal of human genetics 65, 664-670 (1999). 3. Cacace, R., Sleegers, K. & Van Broeckhoven, C. Molecular genetics of early-onset Alzheimer's disease revisited. Alzheimer's & dementia : the journal of the Alzheimer's Association 12, 733-748 (2016). 4. Harper, PS The epidemiology of Huntington's disease. Human genetics 89, 365-376 (1992). 5. Chio, A., et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41, 118-130 (2013). 6. Selkoe, D.J. & Hardy, J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO molecular medicine 8, 595-608 (2016). 7. Ran, F.A., et al. Genome engineering using the CRISPR-Cas9 system. Nature protocols 8, 2281-2308 (2013). 8. Serrano-Pozo, A., Frosch, M.P., Masliah, E. & Hyman, B.T. Neuropathological alterations in Alzheimer disease. Cold Spring Harbor perspectives in medicine 1, a006189 (2011). 9. Braak, H. & Braak, E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiology of aging 18, 351-357 (1997). 10. Ingusci, S., Verlengia, G., Soukupova, M., Zucchini, S. & Simonato, M. Gene Therapy Tools for Brain Diseases. Frontiers in pharmacology 10, 724 (2019). 11. Chan, K.Y., et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nature neuroscience 20, 1172-1179 (2017). 12. Deverman, B.E., et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nature biotechnology 34, 204-209 (2016). 13. Bedbrook, C.N., Deverman, B.E. & Gradinaru, V. Viral Strategies for Targeting the Central and Peripheral Nervous Systems. Annual review of neuroscience 41, 323-348 (2018). 14. Zeng, J., et al. TRIM9-Mediated Resolution of Neuroinflammation Confers Neuroprotection upon Ischemic Stroke in Mice. Cell reports 27, 549-560 e546 (2019). 15. Ortiz-Virumbrales, M., et al. CRISPR / Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer's PSEN2 (N141I) neurons. Acta neuropathologica communications 5, 77 (2017). 16. Gyorgy, B., et al. CRISPR / Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer's Disease. Molecular therapy. Nucleic acids 11, 429-440 (2018). 17. Karczewski, K.J., et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434-443 (2020). 18. Wang, B., et al. Gamma-secretase gene mutations in familial acne inversa. Science 330, 1065 (2010). 19. Mullan, M., et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nature genetics 1, 345-347 (1992). 20. Citron, M., et al. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proceedings of the National Academy of Sciences of the United States of America 91, 11993-11997 (1994). 21. Johnston, J.A., et al. Increased beta-amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell lines from family members with the Swedish Alzheimer's disease APP670 / 671 mutation. FEBS letters 354, 274-278 (1994). 22. Wiedenheft, B., et al. RNA-guided complex from a bacterial immune system enhances target recognition through seed sequence interactions. Proceedings of the National Academy of Sciences of the United States of America 108, 10092-10097 (2011). 23. Gao, X., et al. Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents. Nature 553, 217-221 (2018). 24. Mashiko, D., et al. Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided RNA. Scientific reports 3, 3355 (2013). 25. Zhang, Y., et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 34, 11929-11947 (2014). 26. Oakley, H., et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 26, 10129-10140 (2006). 27. Kimura, R. & Ohno, M. Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiology of disease 33, 229-235 (2009). 28. Shao, C.Y., Mirra, S.S., Sait, H.B., Sacktor, T.C. & Sigurdsson, E.M. Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Abeta and tau pathology in transgenic mouse models of Alzheimer's disease. Acta neuropathologica 122, 285-292 (2011). 29. Gowrishankar, S., et al. Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer's disease amyloid plaques. Proceedings of the National Academy of Sciences of the United States of America 112, E3699-3708 (2015). 30. Sharoar, M.G., Hu, X., Ma, X.M., Zhu, X. & Yan, R. Sequential formation of different layers of dystrophic neurites in Alzheimer's brains. Molecular psychiatry 24, 1369-1382 (2019). 31. Spires-Jones, T.L. & Hyman, B.T. The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron 82, 756-771 (2014). 32. Woodhouse, A., West, A.K., Chuckowree, J.A., Vickers, J.C. & Dickson, T.C. Does beta-amyloid plaque formation cause structural injury to neuronal processes? Neurotoxicity research 7, 5-15 (2005). 33. Jankowsky, J.L., et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Human molecular genetics 13, 159-170 (2004). 34. Garcia-Alloza, M., et al. Characterization of amyloid deposition in the APPswe / PS1dE9 mouse model of Alzheimer disease. Neurobiology of disease 24, 516-524 (2006). 35. Fu, A.K., et al. IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline. Proceedings of the National Academy of Sciences of the United States of America 113, E2705-2713 (2016). 36. Lalonde, R., Kim, H.D., Maxwell, J.A. & Fukuchi, K. Exploratory activity and spatial learning in 12-month-old APP(695)SWE / co+PS1 / DeltaE9 mice with amyloid plaques. Neuroscience letters 390, 87-92 (2005). 37. Choi, J.H., et al. Optimization of AAV expression cassettes to improve packaging capacity and transgene expression in neurons. Mol Brain 7, 17 (2014). 38. Patricio, M.I., Barnard, A.R., Orlans, H.O., McClements, M.E. & MacLaren, R.E. Inclusion of the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances AAV2-Driven Transduction of Mouse and Human Retina. Molecular therapy. Nucleic acids 6, 198-208 (2017). 39. Jawhar, S., Trawicka, A., Jenneckens, C., Bayer, T.A. & Wirths, O. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Abeta aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiology of aging 33, 196 e129-140 (2012). 40. Tible, M., et al. PKR knockout in the 5xFAD model of Alzheimer's disease reveals beneficial effects on spatial memory and brain lesions. Aging cell 18, e12887 (2019). 41. Ran, F.A., et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186-191 (2015). 42. Cruts, M., Theuns, J. & Van Broeckhoven, C. Locus-specific mutation databases for neurodegenerative brain diseases. Human mutation 33, 1340-1344 (2012). 43. Kleinstiver, B.P., et al. Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. Nature biotechnology 33, 1293-1298 (2015). 44. Nagata, K., et al. Generation of App knock-in mice reveals deletion mutations protective against Alzheimer's disease-like pathology. Nature communications 9, 1800 (2018). 45. Park, H., et al. In vivo neuronal gene editing via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer's disease. Nature neuroscience 22, 524-528 (2019). 46. Filser, S., et al. Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions. Biological psychiatry 77, 729-739 (2015). 47. Ou-Yang, M.H., et al. Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice. Science translational medicine 10 (2018). 48. Blume, T., et al. BACE1 Inhibitor MK-8931 Alters Formation but Not Stability of Dendritic Spines. Frontiers in aging neuroscience 10, 229 (2018). 49. Ravindra Kumar, S., et al. Multiplexed Cre-dependent selection yields systemic AAVs for targeting distinct brain cell types. Nature methods 17, 541-550 (2020). 50. Flytzanis, N.C., et al. Broad gene expression throughout the mouse and marmoset brain after intravenous delivery of engineered AAV capsids. BioRxiv, 2020.2006.2016.152975 (2020). 51. Bloch, D.B., et al. Sp110 localizes to the PML-Sp100 nuclear body and may function as a nuclear hormone receptor transcriptional coactivator. Mol Cell Biol 20, 6138-6146 (2000). 52. Mo, W. & Zhang, J.T. Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol 3, 1-27 (2012). 53. Liang, Z., et al. The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines. Nature communications 7, 13282 (2016). 54. Sun, J., et al. CRISPR / Cas9 editing of APP C-terminus attenuates beta-cleavage and promotes alpha-cleavage. Nature communications 10, 53 (2019). 55. Hocquemiller, M., Giersch, L., Audrain, M., Parker, S. & Cartier, N. Adeno-Associated Virus-Based Gene Therapy for CNS Diseases. Human gene therapy 27, 478-496 (2016). 56. Hudry, E. & Vandenberghe, L.H. Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality. Neuron 101, 839-862 (2019). 57. Challis, R.C., et al. Systemic AAV vectors for widespread and targeted gene delivery in rodents. Nature protocols 14, 379-414 (2019). 58. Keane, T.M., et al. Mouse genomic variation and its effect on phenotypes and gene regulation. Nature 477, 289-294 (2011). 59. Wojtowicz, J.M. & Kee, N. BrdU assay for neurogenesis in rodents. Nature protocols 1, 1399-1405 (2006). 60. Styren, S.D., Hamilton, R.L., Styren, G.C. & Klunk, W.E. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 48, 1223-1232 (2000). 61. Seo, J., et al. Activity-dependent p25 generation regulates synaptic plasticity and Abeta-induced cognitive impairment. Cell 157, 486-498 (2014). 62. Lee, K., et al. Replenishment of microRNA-188-5p restores the synaptic and cognitive deficits in 5XFAD Mouse Model of Alzheimer's Disease. Scientific reports 6, 34433 (2016). 63. Devi, L. & Ohno, M. Mitochondrial dysfunction and accumulation of the beta-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice. Neurobiology of disease 45, 417-424 (2012).
[0175] Sequence Listing SEQ ID NO:1: Nucleotide sequence of the sgRNA-Syn::Cas9-mWPRE construct ITR-U6-SW1-Syn-SaCas9-HA-mWPRE-pA-ITR
[0176] SEQ ID NO:2 APP amino acid sequence (alpha secretase site in bold, beta secretase site in underline, and gamma secretase site in double underline) [ka]
Claims
1. 1. A method for treating or reducing the risk of amyloid pathology in an individual in need thereof, comprising: administering to the individual an effective amount of a composition that disrupts an amyloid precursor protein (APP) genomic sequence; The method.
2. 10. The method of claim 1, further comprising sequencing at least a portion of the individual's genome prior to said administering step.
3. The method of claim 1 , wherein the individual's APP genomic sequence comprises at least one mutation.
4. 4. The method of claim 3, wherein the at least one mutation comprises the Swedish mutation (K670N / M671L), the Florida mutation (I716V), the London mutation (V717I), or any combination thereof.
5. 5. The method of claim 4, wherein the at least one mutation comprises the Swedish mutation (K670N / M671L).
6. 2. The method of claim 1, wherein the amyloid pathology is Alzheimer's disease (AD), cerebral amyloid angiopathy, or Down's syndrome.
7. 7. The method of claim 6, wherein the AD is familial AD or sporadic AD.
8. 10. The method of claim 1, wherein the individual has been diagnosed with AD, or the individual has not yet been diagnosed with AD but has known risk factors for AD.
9. 2. The method of claim 1, wherein the composition comprises an siRNA, microRNA, miniRNA, lncRNA, or antisense oligonucleotide targeted to the APP genomic sequence.
10. The composition, (1) an endonuclease guided by a small guide RNA (sgRNA) that targets a location within the APP genomic sequence; and (2) the sgRNA The method of claim 1, comprising one or more vectors encoding
11. 2. The method of claim 1, wherein the sgRNA targets a region in the APP genomic sequence that contains the at least one mutation or a region that contains a beta-secretase cleavage site or a gamma-secretase cleavage site.
12. 11. The method of claim 10, wherein the composition comprises a vector encoding a Cas9 nuclease, preferably Streptococcus pyogenes Cas9 nuclease (SpCas9), and an sgRNA.
13. 12. The method according to claim 10 or claim 11, wherein the one or more vectors are a viral vector, preferably an adeno-associated virus (AAV) vector.
14. 10. The method of claim 1, wherein the composition is administered by subcutaneous, intramuscular, intravenous, intraperitoneal, or intracranial injection, or by oral or nasal administration.
15. 14. The method of claim 13, wherein the composition is administered in the form of a solution, suspension, powder, paste, tablet, or capsule.
16. 1. A kit for treating or reducing the risk of amyloid pathology in an individual in need thereof, comprising: A container containing a composition that disrupts an APP genomic sequence, The kit.
17. 17. The kit of claim 16, wherein the composition is formulated for subcutaneous, intramuscular, intravenous, intraperitoneal, or intracranial injection, or for oral or nasal administration.
18. 17. The kit of claim 16, wherein the composition comprises an siRNA, microRNA, miniRNA, lncRNA, or antisense oligonucleotide targeted to the APP genomic sequence.
19. The composition, (1) an endonuclease guided by a small guide RNA (sgRNA) that targets a position within the APP genomic sequence; and (2) the sgRNA The kit of claim 16, comprising one or more vectors encoding
20. 20. The kit of claim 19, wherein the sgRNA targets a region in the APP genomic sequence that contains the at least one mutation or a region that contains a beta-secretase cleavage site or a gamma-secretase cleavage site.
21. 17. The kit of claim 16, wherein the composition comprises a vector encoding a Cas9 nuclease (preferably Streptococcus pyogenes Cas9 nuclease (SpCas9)) and an sgRNA.
22. The kit according to any one of claims 19 to 21, wherein the one or more vectors are one or more viral vectors, preferably adeno-associated viral (AAV) vectors.
23. 17. The kit of claim 16, wherein the composition is administered by subcutaneous, intramuscular, intravenous, intraperitoneal, or intracranial injection, or by oral or nasal administration.
24. 17. The kit of claim 16, further comprising a second container containing agents for sequencing at least a portion of the individual's genome.
25. 17. The kit of claim 16, further comprising instructions for administration of the composition.
Citation Information
Patent Citations
Methods of diagnosing and treating alzheimer's disease
WO2018204408A1
